CURRICULUM VITAE WILLIAM C. STEWART, MD PRN … · WILLIAM C. STEWART, MD 4 PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES (1) Advisory Board member, Pharmos Pharmaceuticals, 1989

WILLIAM C. STEWART, MD

1

CURRICULUM VITAE


Medical Director PRN Pharmaceutical Research Network, LLC

Director

PRN PharmaFarm, LLC

TABLE OF CONTENTS

CONTACT INFORMATION ................................................................................................... 2

EDUCATION ....................................................................................................................... 3

EXPERIENCE ...................................................................................................................... 3

MEMBERSHIPS ................................................................................................................... 3

BOARD CERTIFICATION ..................................................................................................... 3

PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES ............................................. 4

PHARMACEUTICAL STARTUP DEVELOPMENT CONSULTANT ................................................. 6

VENTURE CAPITAL CONSULTING AND ADVISORY ACTIVITIES ............................................. 6

CORPORATE MEDICAL ADVISORY BOARD ........................................................................... 6 COMPANY BOARD OF DIRECTORS ...................................................................................... 7

PUBLICATIONS .................................................................................................................. 8

INVITED LECTURES ......................................................................................................... 35

MISCELLANEOUS ............................................................................................................. 54

FELLOWS ......................................................................................................................... 54

ACADEMIA ....................................................................................................................... 55

MEETINGS DEVELOPED .................................................................................................... 56


2

CONTACT INFORMATION E-mail: [email protected] Website: http://www.prnorb.com/

Blog: http://prnorb.blogspot.com/ Mobile: +1.843.327.0316 US Headquarters Address: 109 East 17th Street, Suite 3407, Cheyenne, WY 82001 Telephone: +1.307.633.9839 Facsimile: +1.307.633.9840 Administrative Office Address: 104 Berkeley Square Lane, # 286, Goose Creek, SC 29445 Telephone: +1.843.606.0776 Facsimile: +1.888.808.9564

mailto:[email protected]

http://www.prnorb.com/

http://prnorb.blogspot.com/


3

EDUCATION 07/83 to 06/86: Ophthalmology resident, University of Missouri at Kansas City

7/86 to 6/87: Clinical glaucoma fellowship, Duke University Medical Center, Durham, NC. Training under M.

Bruce Shields, MD.

07/82 to 06/83: Private practice, medical director of Minor Emergency Clinic in Garland, TX

07/81 to 06/82: Internal medicine intern at St. Paul Hospital in Dallas, TX

1977 to 1981: Southwestern Medical School, Dallas, TX, Degree earned: MD

1973 to 1977: Southern Methodist University, Dallas, TX, Degree earned: BA (Chemistry)

EXPERIENCE 7/96 to 7/04: Clinical professor of ophthalmology, University of South Carolina, School of Medicine

5/96 to now: Co-Founder and Director of medical affairs, Pharmaceutical Research Network, LLC

7/93 to 5/96: Associate professor of ophthalmology, Storm Eye Institute, Medical University of South Carolina. Chief of the glaucoma service. Granted tenure January 1996.

7/87 to 7/93: Assistant professor of ophthalmology, Storm Eye Institute, Medical University of South Carolina.

Chief of the glaucoma service.

MEMBERSHIPS

American Glaucoma Society

Association for Research in Vision and Ophthalmology - Emeritus

BOARD CERTIFICATION

Diplomat of the American Board of Ophthalmology


4

PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES

(1) Advisory Board member, Pharmos Pharmaceuticals, 1989

(2) Advisory board member, Otsuka America Pharmaceutical, 1994 –1997

(3) Consultant, R+D, Ciba Vision Ophthalmics, 1994 – 1998

(4) Consultant, Marketing, Ciba Vision Ophthalmics, 1996 – 2002

(5) Advisory board member, Sandoz Pharmaceuticals, 1994 - 1995

(6) Worldwide advisory board member, Pharmacia Ophthalmics, 1995

(7) Worldwide advisory board member, Ciba Vision Ophthalmics, 1995

(8) Chairman, US advisory board, Marketing, Ciba Vision Ophthalmics, 1996 –2000

(9) US Director of glaucoma research, Marketing, Ciba Vision Ophthalmics, 2000

(10) Consultant for product development and FDA liaison, Starr Pharmaceutical, 1996

(11) Brimonidine marketing board member, Allergan, 1996

(12) US advisory board member for latanoprost, Pharmacia & Upjohn, 1997

(13) Consultant, Product Development, Sommerset Pharmaceuticals, 1998

(14) Consultant, Product Development, Allergan, 1998

(15) US Glaucoma Advisory board member, Merck, 1998 - 1999

(16) Co-chairman, HMO Advisory Board, Pharmacia, 2002

(17) Consultant, Outcomes, Pfizer, 2003

(18) Consultant, InSite Vision, 2002 – 2003

(19) Board of Advisors, Gerson Lehrman Associates, 2004 – 2005

(20) Consultant, Santen Oy, 2004

(21) Consultant, Merck, 2004

(22) Consultant, Acucela, Inc. 2005

(23) Consultant, Inspire Pharmaceuticals, Inc. 2005

(24) Consultant, Peristat Group, Inc. 2005

(25) Advisory board member, Vistakon Pharmaceuticals, LLC 2006

(26) Consultant, Glaukos 2006


5

PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES (cont.)

(27) Consultant, Vistakon Pharmaceuticals, LLC 2006

(28) Consultant, (OSI) Eyetech, Inc. 2006

(29) Consultant, NovaVision, Inc. 2007

(30) Consultant, XOMA (US), LLC 2007

(31) Consultant, IScience Interventional, 2007

(32) Advisory Board member, NovaVision, Inc. 2007

(33) Advisory Board member, Inspire Pharmaceuticals, Inc. 2007 - 2009

(34) Consultant, Othera Pharmaceuticals, Inc. 2008 - 2009

(35) Consultant, Alcon Laboratories, Inc. 2007 – 2008

(36) Consultant, Vistakon Pharmaceuticals, LLC 2007 - 2009

(37) Consultant, Primus Pharmaceuticals, Inc. 2008 – 2009

(38) Consultant, Icon Bioscience, Inc. 2009 – 2010

(39) Consultant, Sucampo Pharmaceuticals, Inc. 2009

(40) Advisory Board member, Sucampo Pharmaceuticals, Inc. 2009

(41) Consultant, F. Hoffman-La Roche Ltd. 2010-2012

(42) Consultant, Fovea Pharmaceuticals SA 2010

(43) Consultant, Acucela Pharmaceuticals 2010-2012

(44) Consultant, Santen Inc. 2010

(45) Consultant, Altheos, Inc. 2010-2012

(46) Consultant, Inotek Pharmaceuticals Corporation 2010-2011

(47) Consultant, Valeant Pharmaceuticals International, Inc. 2011-2012

(48) Consultant, Sunovion Pharmaceuticals, Inc. 2012

(49) Consultant, Bausch & Lomb, Inc. 2012

(50) Consultant, LayerBio 2013

(51) Clinical Advisory Board, Allysta Pharmaceuticals, Inc. ALY668 2019


6

PHARMACEUTICAL STARTUP DEVELOPMENT CONSULTANT

(1) Consultant, Encore Vision, Inc. 2011-2014

(2) Consultant, BioAvivus, LLC. 2012

(3) Consultant, Aciont, Inc. 2013-

(4) Consultant, Slayback Pharma, LLC 2013

(5) Consultant, Exomemis, Inc. 2013

(6) Consultant, InnoPharma, Inc 2013

(7) Consultant, Trefoil Therapeutics, Inc. 2013-2016

(8) Consultant, Undisclosed 2014-2017

(9) Consultant, ViSci (Visual Sciences), Ltd. 2014

(10) Consultant, Aqua Therapeutics Co., Ltd. 2014

(11) Consultant, iSTAR Medical SA 2014, 2016

(12) Consultant, Renaissance Pharma, Inc. 2014

(13) Consultant, Peregrine Pharmaceuticals Inc. 2016

(14) Consultant, Allysta Pharmaceuticals, Inc. 2016-

(15) Consultant, Undisclosed (mid-sized pharma company with ophtha initiatives) 2016-2018

(16) Consultant, Premark Pharma GmbH 2018

VENTURE CAPITAL CONSULTING AND ADVISORY ACTIVITIES

(1) Consultant, Nordic Biotech 2010

CORPORATE MEDICAL ADVISORY BOARD

(1) Advisory Board member, PRN Consulting Ventures Corporation 2010


7

MEDICAL MONITOR (1) Peregrine CS202-203

(2) ViSci VS101-CS201

(3) Aciont, Inc. DSPV-201

(4) InnoPharma CD-11-265

(5) Icon Bioscience – various protocols

(6) Alcon – various protocols

(7) Allysta Pharmaceuticals, Inc. ALY337

COMPANY BOARD OF DIRECTORS (1) Member, Encore Vision, Inc. 2012-2014

(2) Member, Premark Pharma GmbH 2019

PRECLINICAL/CLINICAL PHARMACEUTICAL DEVELOPMENT

(3) Encore Vision, Inc.

(4) Trefoil Therapeutics, Inc.

(5) Allysta Pharmaceuticals, Inc.

(6) Premark Pharma GmbH

Vice CEO

Encore Vision 2013-14


8

PUBLICATIONS TEXTBOOKS:

(1) Stewart WC, Clinical Practice of Glaucoma, Thorofare: SLACK, Inc., 1990.

TEXTBOOK CHAPTERS:

(1) Stewart WC, Brindley GO, Shields MB. Cyclodestructive Procedures. In: Ritch R, Shields MB, Krupin T

(eds). The Glaucomas (ed. 2). St. Louis: CV Mosby Co., 1995.

(2) Berland JE, Powers TP, Saunders RA, Rowe HE, Wilson ME, Stewart WC. Enhancement of Perkins

tonometry using an external cobalt blue light source. In: Lennerstrand G (ed). Update on Strabismus and Pediatric Ophthalmology. Boca Raton: CRS Press Inc., 1995;9:479-81.

(3) Stewart WC. Glaucoma: Advances in Medical Management. In: Arshinoff S (ed). National Ophthalmic

Speakers Program Proceedings. Montreal: Medicöpea, 1997;8-14.

(4) Stewart WC. New (pending) glaucoma medical therapy. In: Yanoff M, Duker JS (eds). Ophthalmology.

St. Louis: Mosby, Inc., 2004;1553-6.

(5) Konstas AGP, Mikropoulos D, Stewart WC. Fixed Combination Therapy in Glaucoma. In: Shaarawy TM,

Sherwood MB, Hitchings RA, Crowston JG (eds.) Glaucoma. Medical Diagnosis and Therapy. Philadelphia: W.B. Saunders, 2009:565-75.

MONOGRAPHS:

(1) Castelli WP, Stewart WC. Serum lipids and coronary heart disease: implications for the ophthalmologist.

Cosponsored by the Framingham Heart Study and the University of Massachusetts Medical School. OAPI, 1994.

(2) Stewart WC. Glaucoma: Advances in medical management. National Ophthalmic Speakers Program, 1996.

(3) Stewart WC. New and current drug therapy for glaucoma. Ciba Clinical Symposium, 1997.

(4) Stewart WC. Side effects and glaucoma medications. Actualidade Oftalmica 1999;2,No. 1.

(5) Stewart WC. IOP control, neuroprotection and blood flow, putting it all into perspective. Tough on

Pressure, Pharmacia & Upjohn, Canada 1999;9-25.

(6) Higginbotham E, Lee DA, Parrish R, Shaya F, Stewart WC. The impact of hyperemia on compliance, costs, and medical practice. The Ritz-Carlton, Boston, Massachusetts, June 11, 2004 (Ophthalmology Times

2004;29; Supplement 6).

EBOOK:

(1) Stewart WC, Stewart JA. YES™ Your Startup Success. Kindle Direct Publishing, 2018


9

ARTICLES:

(1) Biehl ER, Stewart WC, Marks A, Reeves PC. Influence of the cyano group on orientation of nucleophiles of

aryne. Reaction of isomeric halobenzonitriles with alkali amides in liquid ammonia. J Org Chem 1979;44:3672-5.

(2) Waelterman JM, Cibis GW, Spellman CR, Stewart WC. Racial differences in the cup-to-disc ratios of a normal pediatric population. Glaucoma 1986;8:48-51.

(3) Stewart WC, Sheilds MB. Use of peripheral visual field screening in glaucoma. Invest Ophthalmol Vis

Sci 1987;28:S9.

(4) Reichart R, Stewart WC, Shields MB. Limbus-based versus fornix-based conjunctival flaps in

trabeculectomy. Ophthalmic Surg 1987;18:672-6.

(5) Stewart WC, Shields MB, Ollie AR. Peripheral visual field testing by automated kinetic perimetry in glaucoma. Arch Ophthalmol 1988;106:202-6.

(6) Shields S, Stewart WC, Shields MB. Transpupillary argon laser cyclophotocoagulation in the treatment of glaucoma. Ophthalmic Surg 1988;19:171-5.

(7) Stewart WC, Shields MB. Management of anterior chamber depth after trabeculectomy. Am J

Ophthalmol 1988;106:41-44

(8) Stewart WC, Shields MB. Reply to management of anterior chamber depth after trabeculectomy letter.

Am J Ophthalmol 1988;106:508-9.

(9) Reichert RW, Shields MB, Stewart WC. Intraocular pressure response to replacing pilocarpine with carbachol. Am J Ophthalmol 1988;106:747-8.

(10) Stewart WC, Shields MB. Reply to management of anterior chamber depth after trabeculectomy letter. Am J Ophthalmol 1988;106:767-8.

(11) Stewart WC, Shields MB, Ollie AR. Full threshold versus quantification of defects for visual field testing in

glaucoma. Graefes Arch Clin Exp Ophthalmol 1989;227:51-4.

(12) Martone JF, Shields MB, DePaul KL, Ollie AB, Stewart WC. Correlation of subjective nonautomated visual

field assessment and Vistech contrast sensitivity findings in glaucomatous, ocular hypertensive and age-related normal eyes. Invest Ophthalmol Vis Sci Suppl 1989;30:S177.

(13) Gilpin LB, Stewart WC, Hunt H, Broom C. Components of fluctuations using different Goldmann spot sizes.

Invest Ophthalmol Vis Sci 1989;30:S177.

(14) Stewart WC, Gilpin L, Shields MB, Miller K. Hemianopic offsets in ocular hypertension and glaucoma.


(15) Crosswell HH, Stewart WC, Cascairo M, Hunt H. Components of fluctuation using different background

luminosities. Invest Ophthalmol Vis Sci 1990;31:S17.

(16) Stewart WC, Kulze J, Sutherland S. Factors associated with a learning effect in glaucoma patients using automated perimetry. Invest Ophthalmol Vis Sci 1990;31:S15.

(17) Reynolds M, Stewart WC, Sutherland S. Factors which influence the prevalence of positive catch trials in

glaucoma patients. Graefes Arch Clin Exp Ophthalmol 1990;228:338-41.


10

(18) Gilpin LB, Stewart WC, Shields MB, Miller KN. Hemianopic offsets in the visual field of patients with glaucoma. Graefes Arch Clin Exp Ophthalmol 1990;228:450-3.

(19) Young WO, Stewart WC, Hunt H, Crosswell H. Static threshold variability in the peripheral visual field in

normal subjects. Graefes Arch Clin Exp Ophthalmol 1990;228:454-7.

(20) Weinreb RN, Caldwell DR, Goode SM, Horwitz BL, Laibovitz R, Shrader CE, Stewart RH, Williams AT. A

double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol 1990;110:189-92.

(21) Kulze JC, Stewart WC, Sutherland SE. Factors associated with a learning effect in glaucoma patients using

automated perimetry. Acta Ophthalmol (Copenh) 1990;68:681-6.

(22) Gilpin LB, Stewart WC, Hunt HH, Broom CD. Threshold variability using different Goldmann stimulus sizes.

Acta Ophthalmol (Copenh) 1990;68:674-6.

(23) Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive

glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51-5.

(24) Stewart WC, Shields MB, Miller KN, Blasini M, Sutherland SE. Early postoperative prognostic indicator following trabeculectomy. Ophthalmic Surg 1991;22:23-6.

(25) Pennebaker GE, Stewart WC, Stewart JA, Hunt H. The effect of the stimulus presentation interval upon the

components of fluctuations in automated perimetry. Invest Ophthalmol Vis Sci 1991;32:S1106.

(26) Legler UFC, Assia EI, Hennis HL, Stewart SC, Apple DJ, Carlson AN. Morphologic and histologic analysis of

cyclodestructive procedures in phakic and pseudophakic cadaver eyes. Invest Ophthalmol Vis Sci 1991;32:S747.

(27) Stewart WC. The use of subconjunctival 5-fluorouracil following combined trabeculectomy and cataract

extraction. Invest Ophthalmol Vis Sci 1991;32:S745. (28) McCarty G, Stewart WC, Quayle W, Levin J, Rienhart M. Evaluation of morning IOP control by bedtime

pilocarpine gel dosing. Invest Ophthalmol Vis Sci 1991;32:946.

(29) Crosswell HH, Stewart WC, Cascairo MA, Hunt HH. The effect of background intensity on the components

of fluctuation as determined by threshold-related automated perimetry. Graefes Arch Clin Exp Ophthalmol 1991;229:119-22.

(30) Hennis HL, Assia E, Stewart WC, Legler UFC, Apple DJ. Transscleral cyclophotocoagulation using a

semiconductor diode laser in cadaver eyes. Ophthalmic Surg 1991;22:274-8.

(31) Pennebaker GE, Stewart WC. Response of argon laser trabeculoplasty with varying anterior chamber

anatomy. Ophthalmic Surg 1991;22:301-2.

(32) Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Hoskins HD, Hetherington JN, Bahr RL, Noblin JE,

Delehanty JT. A three-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1991;229:258-61.

(33) Stewart WC, Shields MB. The peripheral visual field in glaucoma: reevaluation in the age of automated

perimetry. Surv Ophthalmol 1991;36:59-69.

(34) Reynolds M, Stewart WC, Sutherland S. Factors which influence the prevalence of positive catch trials in

glaucoma patients. Ophthalmology Digest 1991;3:19-20.


11

(35) Cascairo MA, Stewart WC, Sutherland SE. Influence of missed catch trials on the visual field in normal subjects. Graefes Arch Clin Exp Ophthalmol 1991;229:437-41.

(36) Stewart WC, Cascairo MA, Banta R. The use of a new portable noncontact tonometer in home tonometry. Ann

Ophthalmol 1991;23:377-82.

(37) Assia EI, Hennis HL, Stewart WC, Legler UFC, Carlson AN, Apple DJ. Comparison of Nd: YAG and diode

transscleral cyclophotocoagulation and cyclocryotherapy. Invest Ophthalmol Vis Sci 1991;32:2774-8.

(38) Pennebaker GE, Stewart WC. Temporal visual field in glaucoma: a re-evaluation in the automated perimetry era. Graefes Arch Clin Exp Ophthalmol 1992;230:111-4.

(39) Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Ophthalmology Digest 1991;4:18-9.

(40) Pennebaker GE, Stewart WC, Stewart JA, Hunt HH. The effect of stimulus presentation interval upon the

components of fluctuation in static automated perimetry. Eye 1992;6:353-5.

(41) Hennis HL, Stewart WC. The use of 5-fluorouracil in patients following combined trabeculectomy and

cataract extraction. Ophthalmic Surg 1991;22:451-4.

(42) Stewart WC, Hunt HH. Threshold variation in automated perimetry. Surv Ophthalmol 1993;37:353-61.

(43) Hennis HL, Stewart WC, Neville B, O'Connor KL, Apple DJ. Carcinoma arising in an odontogenic keratocyst

with orbital invasion. Doc Ophthalmol 1991;77:73-9.

(44) Stewart WC, Shields MB, Miller KN, Blasini M, Sutherland SE. Early postoperative prognostic indicators following trabeculectomy. Ophthalmology Digest 1991;22:23-6.

(45) Sponsel WE, DePaul KL, Martone JF, Shields MB, Stewart WC. Association of Vistech contrast sensitivity and visual field findings in glaucoma. Br J Ophthalmol 1992;75:558-60.

(46) Hennis HL, Stewart WC. Semiconductor diode laser transscleral cyclophotocoagulation in patients with

glaucoma. Am J Ophthalmol 1992;113:81-5.

(47) Stewart WC. Static versus kinetic testing in the nasal peripheral field in patients with glaucoma. Acta

Ophthalmol 1992;70:79-84.

(48) Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Hoskins HD, Hetherington JN, Bahr RL, Noblin JE, Delehanty JT. A three-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle

glaucoma. Ophthalmology Digest 1992;18-9.

(49) Hennis HL, Stewart WC. Use of the argon laser to close filtering bleb leaks. Graefes Arch Clin Exp

Ophthalmol 1992;230:537-41.

(50) Stewart WC, Reid KK. Incidence of systemic and ocular disease which may mimic low-tension glaucoma. J

Glaucoma 1992;1:27-31.

(51) Cascairo MA, Stewart WC, Sutherland SE. Reply to: Frankhauser F, Response to influence to missed catch trials on the visual field in normal subjects. Graefes Arch Clin Exp Ophthalmol 1992;230.

(52) Hennis HL, Stewart WC, Jeter EK. Infectious disease risks of fibrin glue (letter). Ophthalmic Surg

1992;23:640.


12

(53) Stewart WC. The 1991 American Glaucoma Society Meeting. 13-14 December, 1991, San Diego, California.

Glaucoma Abstracts International 1992;3:12-4. (54) Stewart WC, Beehler CC, McDonald DK, Croyle TA, Ostrov CS, Rosanelli EG, Crandall AS. The efficacy of

levobunolol 0.25% BID in patients switched from timolol 0.5% BID therapy. Invest Ophthalmol Vis Sci 1992;33:S1122.

(55) Legler UFC, McMillan TA, Stewart WC, Apple DJ. Morphologic, histologic and electron microscopic comparison of diode and argon laser trabeculoplasty in cadaver eyes. Invest Ophthalmol Vis Sci

1992;33:S1159.

(56) Bluestein EC, Stewart WC. Tight versus loose scleral flap suture closure in trabeculectomy surgery. Invest Ophthalmol Vis Sci 1992;33:S1160.

(57) Reid KK, Stewart WC, Kelly DM. Determining visual potential in patients with total cups from glaucoma undergoing combined trabeculectomy and cataract extraction. Invest Ophthalmol Vis Sci

1992;33:S1270.

(58) Nutaitis MJ, Stewart WC, Kelly DM. Use of the pattern discrimination perimeter in patients with glaucoma

and ocular hypertension. Invest Ophthalmol Vis Sci 1992;33:S1384.

(59) Kelly DM, Stewart WC. Long- and short term fluctuation with the pattern discrimination perimeter. Invest Ophthalmol Vis Sci 1992;33:S1384.

(60) Bluestein EC, Stewart WC. Tight versus loose flap closure in trabeculectomy surgery. Doc Ophthalmol

1993;84:379-85.

(61) Nutaitis MJ, Stewart WC, Kelly DM, Hunt HH, Severns ML. Pattern discrimination perimeter testing in

glaucoma and ocular hypertensive patients. Am J Ophthalmol 1992;114:297-301.

(62) Stewart WC, Kelly DM, Hunt HH. Long- and short-term fluctuation on the pattern discrimination perimeter.


(63) McMillan TA, Stewart WC, Legler UFC, Powers T, Nutaitis MJ, Apple DJ. Comparison of diode and argon laser trabeculoplasty in cadaver eyes. Invest Ophthalmol Vis Sci 1994;35:706-10.

(64) McMillan TA, Stewart WC, Nutaitis MJ, Powers TP, Apple DJ. The effect of varying wavelength on subconjunctival scleral laser suture lysis in rabbits. Acta Ophthalmol (Copenh) 1992;:70:758-61.

(65) McMillan TA, Stewart WC, Hunt HH. Association of reliability with reproducibility of the glaucomatous

visual field. Acta Ophthalmol (Copenh) 1992;70:665-70.

(66) Stewart WC. Static versus kinetic testing in the nasal peripheral field in patients with glaucoma.

Ophthalmology Digest 1992 Dec;6-7.

(67) Beehler CC, Stewart WC, MacDonald DK, Croyle TA, Ostrov CS, Rosanelli EG, Crandall AS, Iacono TL, Lue JC, Kelley EP. A comparison of the ocular hypotensive efficacy of twice-daily 0.25% levobunolol to 0.5%

timolol in patients previously treated with 0.5% timolol. J Glaucoma 1992;1:237-42.

(68) McMillan TA, Stewart WC, Hennis HL, Hunt HH, Apple DJ. Histologic differences in the conjunctiva

between black and white glaucoma patients. Ophthalmic Surg 1992;23:762-5.

(69) Hawkins TA, Stewart WC. One year results of semiconductor transscleral cyclophotocoagulation in glaucoma patients. Arch Ophthalmol 1993;111:488-91.


13

(70) McMillan TA, Stewart WC, Hennis HL, Gwynn DR. The association of conjunctival inflammatory cells with

the results of combined cataract extraction and filtration surgery. J Glaucoma 1993;2:193-9.

(71) Stewart WC, Reid KK, Pitts RA. The results of trabeculectomy surgery in African-American versus white glaucoma patients. J Glaucoma 1993;2:236-40.

(72) Gwynn DR, Stewart WC, Hennis HL, McMillan TA, Pitts RA. Association of conjunctival structure and inflammatory cell count to the results of trabeculectomy surgery in primary open-angle glaucoma. Invest

Ophthalmol Vis Sci 1993;34:S724.

(73) Stewart WC, Gwynn DR, Hennis HL, McMillan TA, Pitts RA. The influence of age upon the inflammatory cell counts and structure of conjunctiva in chronic open-angle glaucoma. Invest Ophthalmol Vis Sci

1993;34:S724.

(74) Bluestein EC, Stewart WC. Comparison of single-plate Molteno implantation versus trabeculectomy with 5-

fluorouracil in glaucoma patients at high risk for failure with filtration surgery. Invest Ophthalmol Vis Sci 1993;34:S731.

(75) Chorak RP, Stewart WC. Scotopic vision testing in patients with ocular hypertension and glaucoma. Invest Ophthalmol Vis Sci 1993;34:S1269.

(76) Daroff RB, Frishman WH, Lederman RJ, Stewart WC. Beta-blockers: beyond cardiology. Patient Care

1993;27:47-70.

(77) Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with

advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993;116:176-81.

(78) Hawkins TA, Stewart WC. One-year results of semiconductor transscleral cyclophotocoagulation in patients with glaucoma. Ophthalmology Digest 1993:9-10.

(79) Stewart WC. Avoiding mistakes in interpreting visual fields, Part I: basic concepts. Clinical Signs in Ophthalmology 1993;14:1-14.

(80) Bluestein EC, Stewart WC. Trabeculectomy with 5-fluorouracil versus single-plate Molteno implantation.

Ophthalmic Surg 1993;24:669-73.

(81) Gwynn DR, Stewart WC, Pitts RA, McMillan TA, Hennis HL. Conjunctival structure and cell counts and the

results of filtration surgery. Am J Ophthalmol 1993;116:464-8.

(82) Stewart WC, Hunt HH. Threshold variation in automated perimetry (abstract). Am J Ophthalmol 1993;116:122.

(83) Gwynn DR, Stewart WC, Hennis HL, McMillan TA, Pitts RA. The influence of age upon inflammatory cell counts and structure of conjunctiva in chronic open-angle glaucoma. Acta Ophthalmol (Copenh)

1993;71:691-5.

(84) Stewart WC, Connor AB, Hunt HH. Prediction of postoperative visual acuity in patients with total

glaucomatous cupping using the Potential Acuity Meter and automated perimetry. Ophthalmic Surg 1993;24:730-4.

(85) Fechtner RD, Zimmerman TJ, Katz LJ, Layden WE, Stewart WC, Wise JB. Clinical consultation.

Ophthalmic Practice 1993;11:259-63.

(86) Stewart WC, Crinkley CMC, Murrell HP. Cigarette smoking history in normals, ocular hypertensives and

chronic open-angle glaucoma patients (letter). Am J Ophthalmol 1994;117:267-8.


14

(87) Stewart WC, Pitts RA. Postoperative prognostic indicators following trabeculectomy. Acta Ophthalmol (Copenh) 1993;71:733-8.

(88) Stewart WC. Avoiding mistakes in interpreting visual fields, Part II: Evaluating the printout. Clinical Signs in Ophthalmology 1993;14:1-12.

(89) Gwin TD, Stewart WC, Gwynn DR. Filtration surgery in rabbits treated with diclofenac or prednisolone acetate. Ophthalmic Surg 1994;25:245-50.

(90) Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with

advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993;116:176-81.

(91) Stewart WC, Connor AB, Pitts RA. Prognostic factors and postoperative course following single-plate

Molteno implantation. Doc Ophthalmol 1994;86:409-17.

(92) Carlson AN, Stewart WC, Tso PC. Intraocular lens complications requiring removal or exchange. Surv Ophthalmol 1998;42:417-40.

(93) Stroman GA, Stewart WC, Golnik KC, Curé JA, Olinger R. Evaluation of magnetic resonance imaging in patients with low tension glaucoma. Invest Ophthalmol Vis Sci 1994;35:S1255.

(94) Thompson TL, Hamzavi S, Stewart WC. Use of diagnostic ultrasound in assisting placement of diode

transscleral cyclophotocoagulation applications. Invest Ophthalmol Vis Sci 1994;35:S2172.

(95) Connor AB, Stewart WC, Stroman GA. Optic nerve head characteristics in patients with progressed or

stable ocular hypertension. Invest Ophthalmol Vis Sci 1994;35:S1843.

(96) Odom MD, Stewart WC, Stroman GA. Differences in optic nerve head findings in patients with low-tension glaucoma with or without neurosyphilis. Invest Ophthalmol Vis Sci 1994;35:S1843.

(97) Power TP, Stewart WC, Stroman GA. Ultrastructural characteristics of filtration blebs. Invest Ophthalmol Vis Sci 1994;35:S1421.

(98) Hamzavi S, Stewart WC, Thompson TL. Inter- and intraobserver variation of the optic nerve head in

cadaver eyes using the glaucoma-scope. Invest Ophthalmol Vis Sci 1994;35:S1347.

(99) Stewart WC, Ritch R, Shin D, McCarty G, Rinehart M, Silver L, DeFaller J, Godio L. A double-masked, three

month comparison of the additivity of 0.5% and 1.0% apraclonidine to timolol. Invest Ophthalmol Vis Sci 1994;35:S2176.

(100) Stewart WC. Carteolol, an ophthalmic ß-adrenergic blocker with intrinsic sympathomimetic activity.

J Glaucoma 1994;3:339-45.

(101) Stewart WC, Chauhan BC. Newer visual function techniques in the evaluation of glaucoma. Surv

Ophthalmol 1995;40:119-35.

(101) Stewart WC, Sorrow NA. Evaluation of noninvasive carotid studies in patients with low-tension glaucoma

(letter). Acta Ophthalmol (Copenh) 1994;72:398.

(103) Stewart WC, Crinkley CMC. Influence of serous suprachoroidal detachments on the results of trabeculectomy surgery. Acta Ophthalmol (Copenh) 1994;72:309-14.

(104) Nutaitis MJ, Stewart WC, Kelly DM. Musterunterscheidungsperimetrie bei Patienten mit Glaukom und

okulärer Hypertension. Search on Glaucoma 1994;2:99.


15

(105) Stewart WC, Reid KK, Pitts RA. The results of trabeculectomy surgery in African-American versus white

glaucoma patients (abstract). Am J Ophthalmol 1994;117:552.

(106) Stewart WC, Chorak RP, Murrell HP. Evaluation of the whole-field scotopic retinal sensitivity tester in clinical glaucoma practice. J Glaucoma 1994;3:280-85.

(107) Hamzavi R, Stewart WC, Thompson TL. Use of diagnostic ultrasound in placing diode transscleral cyclophotocoagulation applications (letter). Am J Ophthalmol 1994;118:667-8.

(108) Hawkins TA, Stewart WC, McMillan TA, Gwynn DR. Analysis of diode, argon, and Nd:YAG peripheral

iridectomy in cadaver eyes. Doc Ophthalmol 1994;87:367-76.

(109) Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, Van Buskirk EM. The efficacy of apraclonidine as

an adjunct to timolol therapy. Arch Ophthalmol 1995;113:287-92.

(110) Stewart WC, Crinkley CMC, Carlson AN. Results of trabeculectomy combined with phacoemulsification versus trabeculectomy combined with extracapsular cataract extraction in patients with advanced

glaucoma. Ophthalmic Surg 1994;25:621-7.

(111) Stewart WC. The effect of lifestyle on the relative risk to develop open-angle glaucoma. Current Opin

Ophthalmol 1995;6:3-9.

(112) Stroman GA, Stewart WC, Golnik KC, Curé JK, Olinger RE. Magnetic resonance imaging in patients with low-tension glaucoma. Arch Ophthalmol 1995;113:168-72.

(113) Stewart WC, Konstas AGP. The diagnosis and treatment of glaucoma suspects. Ophthalmologica 1994;6:410-18.

(114) Stewart WC, Crinkley CMC, Carlson AN. Fornix- vs. limbus-based flaps in combined phacoemulsification

and trabeculectomy. Doc Ophthalmol 1994;88:141-51.

(115) Hamzavi S, Stewart WC, Jackson G, Thompson TL. Reproducibility of the Glaucoma-scope in cadaver eyes.

Acta Ophthalmol Scand 1995;75:264-7.

(116) Stewart WC, Crinkley CMC, Carlson AN. Results of combined phacoemulsification and trabeculectomy in

patients with elevated preoperative intraocular pressures. J Glaucoma 1995;4:164-9

(117) Jackson GJ, Want X-H, Stewart WC. Differences in optic disc in LTG patients with relatively low or high pressures. Invest Ophthalmol Vis Sci 1995;36:S78.

(118) Blessing WD, Detkova D, Stewart WC, Stroman GA. Evaluation of short-term fluctuation in pattern

discrimination perimetry. Invest Ophthalmol Vis Sci 1995;36:S337.

(119) Rogers GM, Stewart WC, Crinkley CMC, Carlson AN. Effect of cataract extraction on automated fields in

chronic open-angle glaucoma. Invest Ophthalmol Vis Sci 1995;36:S339.

(120) Powers TP, Stroman GA, Stewart WC, Wang X-H, Hamzavi S. Use of indocyanine green to enhance the

effect of diode transscleral cyclophotocoagulation in a cadaver eye model. Invest Ophthalmol Vis Sci 1995;36:S556.

(121) Stroman GA, Hamzavi S, Stewart WC, Blessing WD, Powers T. Comparison of contact transscleral

semiconductor diode laser cyclophotocoagulation versus non-contact technique in cadaver eyes. Invest Ophthalmol Vis Sci 1995;36:S559.


16

(122) Stewart JA, Stroman GA, Stewart WC. Safety of the washout period of -adrenergic blockers used in

clinical trials. Invest Ophthalmol Vis Sci 1995;36:S737.

(123) Scafidi AF, Stewart WC, Ropo AM and Timolol Hemihydrate Study Group. Safety and efficacy of timolol

hemihydrate 0.25 and 0.5% ophthalmic solution in open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 1995;36:S737.

(124) Stewart WC, Ritch R, Laibovitz R, McCarty G, Silver L, DeFaller J. A double-masked, 90 day study of the efficacy of 0.25% and 0.5% apraclonidine versus timolol. Invest Ophthalmol Vis Sci 1995;36:S738.

(125) Marotto Me, Hamzavi S, Stewart WC, Stroman GA, Wang X-H, Powers TP, Rogers GM, Greene WB.

Morphologic changes in the trabecular meshwork following phacoemulsification in a cadaver eye model.


(126) Hamzavi S, Stewart WC, Stroman GA, Blessing WD. Accuracy model for Glaucoma-Scope optic nerve head topographical measurements. Invest Ophthalmol Vis Sci 1995;36:S970.

(127) Stewart WC, Hamzavi S, Stroman GA. Evaluating the accuracy of digitalized retinal images using laser

induced changes to the optic disc in a cadaver eye model. Invest Ophthalmol Vis Sci 1995;36:S971.

(128) Stewart WC, Connor AB, Wang X-H. Anatomic features of the optic disc and risk of progression in ocular

hypertension. Acta Ophthalmol Scand 1995;73:237-41.

(129) Stewart WC, Rogers GM, Crinkley CMC, Carlson AN. Effect of cataract extraction on automated fields in

chronic open-angle glaucoma. Arch Ophthalmol 1995;113:875-9.

(130) Stewart WC. Megatrends in glaucoma meds. Review Ophthalmol 1995;79-83.

(131) Stewart WC, Connor AB, Rogers GM. Correlation of pattern discrimination perimetry to the optic disc and visual field in ocular hypertensive and chronic open-angle glaucoma patients. Int Ophthalmol

1995;19:101-7.

(132) Stewart WC, Crinkley CMC, Carlson AN. Fornix- vs. limbus-based flaps in combined phacoemulsification

and trabeculectomy. Ophthalmology Digest 1995;27-8.

(133) Stroman GA, Stewart WC, Golnik KC. Magnetic resonance imaging in patients with low-tension glaucoma -

in reply. Arch Ophthalmol 1996;114:105.

(134) Stroman GA, Stewart WC. Magnetic resonance imaging in patients with low-tension glaucoma - in reply. Arch Ophthalmol 1995;113:1229

(135) Stroman GA, Stewart WC, Golnik KC, Curé JK, Olinger RE. Magnetic resonance imaging in patients with low-tension glaucoma. Year Book of Ophthalmology 1996.

(136) Stroman GA, Stewart WC, Wang X-H, Hamzavi S, Powers TP. Use of ICG with diode transscleral

cyclophotocoagulation in a cadaver eye model. Ophthalmic Surg Lasers 1995;26:582-3.

(137) Stewart WC, Crinkley CMC, Carlson AN. Prognostic factors in long-term intraocular pressure control

following combined phacoemulsification and trabeculectomy. Acta Ophthalmol Scand 1996;74:145-50.

(138) Stewart WC. Discussion of Cases in Controversy. J Glaucoma 1995.

(139) Stewart WC. Timolol hemihydrate - a new formulation of timolol for the treatment of glaucoma. J Ocul

Pharmacol Ther 1996;12:225-37.


17

(140) Stroman GA, Stewart WC, Hamzavi S, Powers TP, Blessing WD. Contact versus non-contact diode

transscleral cyclophotocoagulation in cadaver eyes. Ophthalmic Surg Lasers 1996;27:60-5.

(141) Powers TP, Stewart WC, Stroman GA. Ultra structural features of filtration blebs with different clinical appearances. Ophthalmic Surg Lasers 1996;27:790-4.

(142) Wang X-H, Stewart WC, Jackson GJ. Differences in optic discs in low-tension glaucoma patients with relatively low or high pressures. Acta Ophthalmol Scand 1996;74:364-7.

(143) Stewart WC, Castelli WP. Systemic side effects of topical β-adrenergic blockers. Clin Cardiol

1996;19:691-7.

(144) Stewart WC, Odom MB, Stroman GA. The optic disc in low-tension glaucoma patients with or without

positive syphilis serology. Ann Ophthalmol Glaucoma 1996.

(145) Stewart WC, Chorak RP, Murrell HP. Evaluation of the whole-field scotopic retinal sensitivity tester in clinical glaucoma practice. Search on Glaucoma 1996.

(146) Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Search on Glaucoma 1996.

(147) Stewart WC. New Glaucoma Medicines: Update 1996. Review Ophthalmol 1996;74-9.

(148) Stewart WC. Effects and side effects of apraclonidine. Klin Monatsbl Augenheilkd 1996;209:A7-13.

(149) Dubiner HB, Hill R, Kaufman H, Keates EU, Zimmerman TJ, Mandell AI, Mundorf TK, Bahr RL, Schwartz LW, Towey AW, Hurvitz LM, Starita RJ, Sassani JW, Ropo A, Gunn R, Stewart WC. Timolol hemihydrate vs.

timolol maleate in ocular hypertension and open-angle glaucoma. Am J Ophthalmol 1996;121:522-8.

(150) Stewart WC. Prostaglandin analogues: their usage and benefits in glaucoma treatment. Ophthalmic

Practice 1996;14:48-55.

(151) Stewart WC, Laibovitz R, Horwitz B, Stewart RH, Ritch R, Kottler M, and the Apraclonidine Primary Therapy Study Group. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs. 0.5%

timolol. Arch Ophthalmol 1996;114:938-42.

(152) Stewart WC, Chauhan BC. Newer visual function tests in the evaluation of glaucoma (abstract). Am J

Ophthalmol 1996;121:235.

(153) Konstas AGP, Mantziris DA, Stewart WC. Comparison of IOP diurnal variation in newly diagnosed, untreated patients with exfoliation glaucoma and POAG. Invest Ophthalmol Vis Sci 1996;37:S821.

(154) Hamzavi S, Stewart WC, Hamzavi SL, Stroman GL. Transcranial Doppler in progressed and stable ocular hypertensive patients. Invest Ophthalmol Vis Sci 1996;37:S31.

(155) Jiang WJ, Ma JX, Stewart WC. Binding of timolol to ocular tissues in not though 3-adrenergic receptor.


(156) LoPresto C, Ragaiey T, Ma JX, Stewart WC. Optic nerve axon loss in superglue induced IOP elevation in

rats. Invest Ophthalmol Vis Sci 1996;37:S830.

(157) Sine C, Stewart WC. Long term follow-up of IOP control in glaucoma patients stabilized on Iopidine® for at least six months. Invest Ophthalmol Vis Sci 1996;37:S1102.


18

(158) Stewart JA, Stewart WC, Sutherland C, Sine CS. Cholesterol as a risk factor for elevated IOP. Invest


(159) Stroman GA, LoPresto C, Stewart WC, Kent DG, Greene WB. Trabecular meshwork changes occurring with phacoemulsification in canine eyes. Invest Ophthalmol Vis Sci 1996;37:S824.

(160) Ragaiey T, Ma JX, Seigel GM, Jiang WJ, Stewart WC. L-deprenyl increases the survival of retinal neuronal

cell line E1A-NR3 dying by apoptosis. Invest Ophthalmol Vis Sci 1996;37:S830.

(161) Stewart WC, Konstas AGP, Stroman GA, Since CS. Clinical presentation of glaucoma in patients with exfoliation glaucoma versus POAG. Invest Ophthalmol Vis Sci 1996;37:S821.

(162) Darby WF, Kent AR, Stewart WC. Comparison of optic nerve head findings and ischemic lesions in low-

tension glaucoma patients. Invest Ophthalmol Vis Sci 1996;37:S29.

(163) Stewart WC, Sine CS, Carlson AN. Three-millimeter versus six-millimeter incisions in combined

phacoemulsification and trabeculectomy. Ophthalmic Surg Lasers 1996;27:832-8.

(164) Stroman GA, Stewart WC, Golnik KC, Curé JK, Olinger RD. Magnetic resonance imaging in patients with

low-tension glaucoma. Arch Ophthalmol (India) 1996;3:192-6.

(165) Golnik KC, Hund PW, Stroman GA, Stewart WC. Magnetic resonance imaging in patients with unexplained optic neuropathy. Ophthalmology 1996;103:515-20.

(166) Konstas AGP, Mantziris DA, Stewart WC. IOP diurnal curve in newly diagnosed patients with exfoliation

glaucoma and primary open-angle glaucoma. Ophthalmologica (Greece) 1996;8:32-8.

(167) Stewart WC, Sine C, Sutherland S, Stewart JA. Total cholesterol and high density lipoprotein as risk factors

for increased intraocular pressure. Am J Ophthalmol 1996;122:575-7.

(168) Stewart WC, Sine CS, LoPresto C. Surgical versus medical management of chronic open-angle glaucoma.


(169) Konstas AGP, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:182-5.

(170) Konstas AGP, Stewart WC, Stroman GA, Sine CS. Clinical presentation and initial treatment patterns in patients with exfoliation glaucoma versus primary open-angle glaucoma. Ophthalmic Surg Lasers

1997;28:111-7.

(171) Stroman GA, Stewart WC, Stewart JA. Safety of ß-adrenergic blocker washout period in clinical trials. Acta Ophthalmol Scand 1997;75:94-5.

(172) Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, Van Buskirk EM. The efficacy of apraclonidine as an adjunct to timolol therapy. Search on Glaucoma 1996;4:96.

(173) Stewart WC. Chronic open-angle glaucoma and lifestyle. Prog Retin Eye Res 1997;16:567-90.

(174) Stewart WC, Garrison P. Glaucoma treatment comes of age: New approaches in primary care. Review Ophthalmol 1997 March;119-22.

(175) Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL, and the NIGHT study group. Cardiovascular

effects of topical carteolol and timolol in patients with ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol 1997;123:465-77.


19

(175) Stewart WC, Sine C, Cate E, Minno GE, Hunt HH. Daily cost of ß-adrenergic blocker therapy. Arch

Ophthalmol 1997;115:853-6.

(177) Ragaiey T, Ma J-X, Jiang W-J, Greene W, Seigel GM, Stewart WC. L-deprenyl protects injured retinal precursor cells in vitro. J Ocular Pharmacol Ther 1997;13:479-88.

(178) Stewart WC, Sine C. Reply to letter to editor regarding: Surgical versus medical management of chronic open-angle glaucoma. Am J Ophthalmol 1997;123:860-2.

(179) Stewart JA, Kent AR, Dubiner HB, Whitaker R, Mundorf TK, Stewart WC. The efficacy and safety of

diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-c. Invest Ophthalmol Vis Sci 1997;38:S1295.

(180) Sine CS, Stewart WC, Stewart JA, Solomon KD. Changes in corneal analysis following phacoemulsification and posterior chamber lens insertion. Invest Ophthalmol Vis Sci 1997;38:S3984.

(181) Mundorf TK, Sine CS, Otero D, Stewart JA, Stewart WC. Safety and efficacy of switching timolol maleate

solution to timolol hemihydrate (Betimol™) 0.5% given twice daily. Invest Ophthalmol Vis Sci

1997;38:S2594.

(182) Mantziris DA, Konstas AGP, Maltezos A, Stewart WC. Diurnal variation of intraocular pressure in exfoliation or primary open-angle glaucoma patients treated with timolol 0.5% and timolol gel forming ophthalmic

solution. Invest Ophthalmol Vis Sci 1997;38:S2593.

(183) Konstas AGP, Mantziris DA, Cate EA, Stewart WC. Diurnal variation of intraocular pressure in patients with

exfoliation glaucoma or primary open-angle glaucoma treated with timolol 0.5%. Invest Ophthalmol Vis Sci 1997;38:S2592.

(184) Solomon KD, Stewart WC, Hunt HH, Cate EA. Intracameral carbachol 0.01% in phacoemulsification and

posterior chamber lens implantation. Invest Ophthalmol Vis Sci 1997;38:S1297.

(185) Gasper JR, Stewart JA, Leland T, Stewart WC. Efficacy and safety of Betimol™ (timolol hemihydrate

solution) given once daily versus Timoptic-XE™ given once daily in the treatment of elevated intraocular pressure. Invest Ophthalmol Vis Sci 1997;38:S2590.

(186) Laibovitz RA, Dubiner HB, Sall KN, Mundorf TK, Katz LJ, Singh K, Shulman DG, Siegel LI, Nussbaum LL, Stewart WC. Ocular tolerability and intraocular pressure effects of carteolol and timolol in older women

with ocular hypertension or primary open-angle glaucoma. Invest Ophthalmol Vis Sci 1997;38:S2586.

(187) Pruitt CA, Stewart WC, Solomon KD. Changes in visual fields following phacoemulsification and posterior chamber IOL insertion. Invest Ophthalmol Vis Sci 1997;38:S2641.

(188) Cate EA, Stewart WC, Sine CS, Minno GE, Hunt HH. Daily cost of -adrenergic blocker therapy. Invest


(189) Stewart WC, Dubiner HB, Laibovitz RA, Sall KN, Mundorf TK, Katz LJ, Singh K, Shulman DG, Siegel LI, Nussbaum LL. The effect of carteolol and timolol on plasma lipid profiles in older women with ocular

hypertension or primary open-angle glaucoma. Invest Ophthalmol Vis Sci 1997;38:S2591.

(190) Konstas AGP, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in

exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:975-9.

(191) Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL and the Nocturnal Investigation of Glaucoma

Hemodynamics Trial Study Group. Efficacy of carteolol 1% versus timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol 1997;124:498-505.


20

(192) Solomon KD, Stewart WC, Hunt HH, Cate EA. Intracameral carbachol 0.01% in phacoemulsification and posterior chamber lens implantation. Am J Ophthalmol 1998;125:36-43.

(193) Stewart WC, Garrison PM. ß-blocker-induced complications and the glaucoma patient: newer treatments to

help reduce systemic side effects. Arch Intern Med 1998;158:221-6.

(194) Stewart WC. Case reports. Review Ophthalmol 1997;6:50-4.

(195) Mundorf TK, Cate EA, Sine CS, Otero DW, Stewart JA, Stewart WC. The safety and efficacy of switching

timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocular Pharmacol Ther 1998;14:129-35.

(196) Stewart WC. When to switch patients to one of the new glaucoma medications. Review Ophthalmol 1998;76-82.

(197) Stewart WC. Towards a new blood flow product. Review Ophthalmol 1998;137-40.

(198) Kent AR, Dubiner HB, Whitaker R, Mundorf TK, Stewart JA, Cate EA, Stewart WC. The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C.

Ophthalmic Surg Lasers 1998;29:562-9.

(199) Stewart WC, Pruitt CA, Cate EA, Bean GW. Ophthalmologists’ treatment practices regarding elevated intraocular pressure. Invest Ophthalmol Vis Sci 1998;38:S33.

(200) Louden TA, Smith SL, Pruitt CA, Sine CS, Stewart WC. The use of latanoprost 0.05% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Invest


(201) Clifford TB, Smith SL, Sine CS, Pruitt CA, Hudgins AC, Stewart WC. The use of latanoprost 0.05% once

daily to reduce the intraocular pressure in patients with uveitis. Invest Ophthalmol Vis Sci 1998;38:S256.

(202) Seabrook CD, Smith SL, Sine SL, Pruitt CA, Stewart WC. The influence of latanoprost 0.005% once daily as primary or adjunctive therapy on intraocular pressure. Invest Ophthalmol Vis Sci 1998;39:S257.

(203) Stewart JA, Koester J, Kapik B, Pugh S, Stewart WC. The IOP diurnal curve in COAG or OHT patients treated with Rescula® 0.12% or timolol maleate 0.5%. Invest Ophthalmol Vis Sci 1998;39:S481.

(204) Konstas AGP, Maltezos A, Bufidis T, Hudgins AC, Stewart WC. 24 hour control of IOP with dorzolamide and

timolol maleate in exfoliation and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 1998;39:S708

(205) Hudgins AC, Pruitt CA, Sine CS, Stewart JA, Stewart WC. Drop characteristics of latanoprost, brimonidine, apraclonidine, dorzolamide, timolol solution and Timoptic-XE®. Invest Ophthalmol Vis Sci

1998;39:S709.

(206) Stewart WC, Osterman J. Serum lipid physiology and the influence of glaucoma medications. Surv

Ophthalmol 1998;43:233-44.

(207) Smith SL, Sine CS, Pruitt CA, Stewart WC. The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or adjunctive therapy. J Ocular Pharmacol Ther 1999;15:29-39.

(208) Stewart WC, Stewart JA, Kapik BM. The effect of unoprostone isopropylate 0.12% vs. timolol maleate

0.5% on the diurnal IOP. J Glaucoma 1998;6:388-97.


21

(209) Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily vs. timolol gel in treating elevated IOP. J Glaucoma 1998;7:402-47.

(210) Stewart WC. New perspectives in the medical treatment of glaucoma. Current Opin Ophthalmol

1999;10:99-108.

(211) Stewart WC, Dubiner HB, Mundorf TK, Laibovitz RA, Sall KN, Katz LJ, Singh K, Shulman DG, Siegel LI,

Hudgins AC, Nussbaum L, Apostolaros M. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol 1999;127:142-7.

(212) Stewart WC, Cate EA, Stewart JA. Systemic ß-blockade with once daily Betimol or Timoptic-XE. J Ocular

Pharmacol Ther 1999;15:225-31.

(213) Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. The use of latanoprost 0.005% once daily to

simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 1999;77:189-92.

(214) Stewart WC. Current trends in stepwise therapy. Review Ophthalmol 1999;60-4.

(215) Camras CB, Wax MB, Ritch R, Weinreb R, Robin Al, Higginbotham EJ, Lustgarten J, Stewart WC, Sherwood M, Krupin T, Wilensky J, Cioffi GA, Katz LJ, Schumer RA, Kaufman PL, Minckler D, Zimmerman T,

Stjernschantz J, and the United States Latanoprost Study Group. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. Am J Ophthalmol 1998;126:390-9.

(216) Konstas AGP, Maltezos A, Mantziris DA, Sine CS, Stewart WC. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients. Eye

1999;13:314-8.

(217) Holmes KT, Sharpe ED, Day DC, Dubiner H, Stewart WC. Efficacy and safety of timolol hemihydrate 0.5%

solution once daily versus timolol maleate gel 0.5% once daily added to latanoprost 0.005%. Invest Ophthalmol Vis Sci 1999;40:S664.

(218) Stewart WC, Halper LK, Najarian D, Johnson-Pratt L, Hartenbaum D. Tolerability and efficacy of

dorzolamide versus acetazolamide in patients with ocular hypertension or open-angle glaucoma. Invest


(219) Leech JN, Sharpe ED, Lee WH, Kolker AE, Day DG, Stewart WC. Latanoprost, brimonidine and dorzolamide

used as adjunctive therapy added to -blocker therapy in ocular hypotensive and primary open-angle

glaucoma patients. Invest Ophthalmol Vis Sci 1999;40:S665.

(220) Schuhr J, Neubert B, Harris J, Kaye B, Stewart WC. Benefit of an educational program on disease awareness and compliance in patients with glaucoma. Invest Ophthalmol Vis Sci 1999;40:S195.

(221) Konstas AGP, Mantziris DA, Maltezos A, Cate EA, Stewart WC. Comparison of 24 hour control with

timoptic® 0.5% and timoptic-XE™ 0.5% in exfoliation and primary open-angle glaucoma. Acta Ophthalmol Scand 1999;77:541-3.

(222) Stewart WC, Hudgins AC, Pruitt CA, Sine C. Daily cost of newer glaucoma agents. J Ocul Pharmacol Ther 1999;15:379-88.

(223) Konstas AGP, Maltezos AC, Gandi S, Hudgins AC, Stewart WC. Comparison of the 24 hour intraocular

pressure reduction with two dosing regimes of latanoprost and timolol in patients with open-angle

glaucoma. Am J Ophthalmol 1999;128:15-20.


22

(224) Stewart WC. Glaucoma Medications and their side effects. Ophthalmic Practice 1999;17:2.

(225) Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis.

Acta Ophthalmol Scand 1999;77:668-72.

(226) Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol

solution once daily vs. timolol gel added to latanoprost. Am J Ophthalmol 1999;128:692-6.

(227) Stewart WC, Sharpe ED, Day DG, Kolker AE, Konstas AGP, Lee WH, Reiser JC, Chopra H, Holmes KT. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or

dorzolamide 2% when added to a topical -adrenergic blocker in patients with primary open-angle

glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000;16:251-9.

(228) Konstas AGP, Maltezos A, Bufidis T, Hudgins AC, Stewart WC. 24 hour control of IOP with dorzolamide and

timolol maleate in exfoliation and primary open-angle glaucoma. Eye 2000;14:73-7.

(229) Stewart WC, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT, Stewart JA. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce the intraocular pressure. Am J Ophthalmol

2000;129:723-7.

(230) Stewart WC, Kolker AE, Sharpe ED, Day DG, Holmes KT, Leech JN, Johnson M, Cantrell JB. Factors

associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 2000;130:274-9.

(231) Konstas AGP, Lake S, Maltezos T, Holmes KT, Stewart WC. Latanoprost compared to pilocarpine as third line therapy in exfoliation glaucoma. Invest Ophthalmol Vis Sci 2000;41:S514.

(232) Albritton AE, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT, Stewart JA, Stewart WC. Brimonidine

0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Invest Ophthalmol Vis Sci 2000;41:S514.

(233) Stewart JA, Stewart WC, Crockett S, Peloso C, Brown A, Zhu HJ, Shams N. Effect of unoprostone isopropyl0.15% or timolol maleate 0.5% ophthalmic solutions versus placebo on cardiovascular function in

healthy subjects. Invest Ophthalmol Vis Sci 2000;41:S514.

(234) Lindsay CL, Stewart JA, Day DG, Holmes KT, Stewart WC. The effect of timolol maleate 0.5% gel and

timolol maleate 0.5% solution twice daily versus placebo on pulmonary function in older primary open-

angle glaucoma or ocular hypertensive patients. Invest Ophthalmol Vis Sci 2000;41:S515.

(235) Stewart WC, Walters TR, Day, DG, Evans RM, Friedlaender MH, Chen CE. Effects of ISV-205 (diclofenac in

DuraSite®) on cortiocosteriod-induced IOP response in glaucoma relatives. Invest Ophthalmol Vis Sci 2000;41:S51

(236) Johnson MA, Kolker AE, Sharpe ED, Day DG, Holmes KT, Leech JN, Cantrell JB, Stewart WC. Factors

associated with long-term progression or stability in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2000;41:S518.

(237) Dirks M, DuBiner H, Cooke D, Stewart W, Drain C, Felix C, VanDenburgh A. Efficacy and safety of the ocular hypotensive lipid AGN-192024 in patients with elevated IOP: A comparison with latanoprost.


(238) Small DS, Acheampong A, Reis B, Stewart W, Berdy G, Epstein R, Foerster R, Forstot L, Tang-Liu D. Blood

concentrations of cyclosporian A (CsA) during twice-daily treatment of 0.05% and 0.1% cyclosporine

ophthalmic emulsions in patients with moderate to severe keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 2000;41:S359.


23

(239) Stewart WC, Day DG, Stewart JA, Holmes KT, Leech JN, Rowan CT, Schwartz GF. Therapeutic success of

Latanoprost 0.005% compared to Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension. J Ocul Pharmacol Ther 2000;16:557-64.

(240) Lee DA, Fechtner RD, Fiscella RG, Singh K, Stewart WC. Emerging perspectives on glaucoma: highlights of a roundtable discussion. Am J Ophthalmol 2000;130:S1-11.

(241) Stewart WC. Survey Assesses How US Physicians Treat Glaucoma. Review Ophthalmol 2001:64-8.

(242) Netland P, Stewart WC. Glaucoma drugs: safer, more powerful and more to come (Review). Review Ophthalmol 2000:41-50.

(243) Stewart WC, Stewart JA, Holmes KT, Leech JN. Differences in ocular surface irritation between timolol hemihydrate and maleate. Am J Ophthalmol 2000;130:712-6.

(244) Stewart WC. Four ways to make visual field exams more accurate. Here’s how to use this in-office consultant better. Review Ophthalmol 2000;7:48.

(245) Konstas AGP, Lake S, Maltezos AC, Holmes KT, Stewart WC. 24 hour intraocular pressure reduction with

latanoprost compared to pilocarpine as third line therapy in exfoliation glaucoma. Eye 2001;15:59-62.

(246) Stewart WC, Sharpe ED, Stewart JA, Holmes KT, Latham KE. Additive efficacy of unoprostone isopropyl

0.12% (Rescula) to latanoprost 0.005%. Am J Ophthalmol 2001;131:339-44.

(247) CIBA symposium on Rescula. New Strategies in the management of Glaucoma. Supplement Review of

Ophthalmol June 2001.

(248) Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J

Ophthalmol 2001;131:631-5.

(249) Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%.


(250) Stewart WC. Evaluating a New Glaucoma Drop. Ophthalmol Management 2001:14-7.

(251) Stewart WC, Day DG, Holmes KT, Stewart JA. Effect of timolol 0.5% gel and solution on pulmonary

function in older glaucoma patients. J Glaucoma 2001;10:227-32.

(252) Konstas AGP, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or

three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 2001;131:729-33.

(253) Jackson AL, Stewart WC, Stewart JA, Holmes KT. Cardiovascular effects of timolol, brimonidine and

brimonidine/timolol in combination. Invest Ophthalmol Vis Sci 2001;42:S418.

(254) Konstas AGP, Holmes KT, Stewart WC. A comparison of the efficacy and safety of latanoprost 0.005%

every evening versus timolol/dorzolamide fixed combination twice daily. Invest Ophthalmol Vis Sci 2001;42:S420.

(255) Stewart WC, Mundorf T, Haque R, Brown A, Kapik B, Shams N, Unoprostone Study Group. Comparison of

the IOP-lowering efficacy and safety of the docosanoid unoprostone isopropyl 0.15% versus timolol maleate 0.5% dosed twice daily for 6 months in patients with primary open-angle glaucoma or ocular

hypertension. Invest Ophthalmol Vis Sci 2001;42:S557


24

(256) DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in

patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv Ophthalmol 2001;45:S353-360.

(257) Stewart WC. Emerging therapies in the medical management of glaucoma. Review Ophthalmol 2001 June:9-23.

(258) Stewart WC. Diurnal Curves Truly Measure Efficacy. Review Ophthalmol 2001 Nov;128-32.

(259) Stewart WC. Maximizing medical therapy for glaucoma. Review Ophthalmol 2002 Feb;39-45.

(260) Stewart WC. How the new prostaglandins stack up: A look at what clinical studies reveal about travoprost

and bimatoprost in relation to latanoprost. Review Ophthalmol 2002 June.

(261) Stewart WC, Halper LK, Johnson-Pratt L, Polis A, Hartenbaum D. Tolerability and efficacy of dorzolamide

versus acetazolamide added to timolol. J Ocul Pharmacol Ther 2002;18:211-20.

(262) Stewart WC. Reading between the lines: An interpretation of clinical studies. J Ophthalmic Practice

2002;20:81-2.

(263) Stewart WC, Rhodes JS, Leech JN. Survey assesses red eye and prostaglandin use. Review Ophthalmol 2002 Apr:72-73.

(264) Konstas AGP, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC. A comparison of once daily morning versus evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002;133:753-757.

(265) Small DS, Acheampong A, Reis B, Stern K, Stewart W, Berdy G, Epstein R, Foerster R, Forstot L, Tang-Liu

DD. Blood concentrations of cyclosporine A during long-term treatment with cyclosporine A ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 2002;18:411-

418.

(266) Stewart WC, Stewart JA, Crockete S, Kulilus C, Brown A, Shams N. Comparison of the cardiovascular

effects of unoprostone 0.15%, timolol 0.5%, and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol Scand 2002;80:272-276.

(267) Stewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or

brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmol Scand 2002;80:277-281.

(268) Stewart WC, Leech J, Sharpe ED, Kulze J, Ellyn J, Day DG. An economic analysis of switching to latanoprost

from a -blocker or adding brimonidine or latanoprost to a -blocker in open-angle glaucoma or ocular

hypertension. Am J Manag Care 2002;8:S240-248.

(269) Stewart WC, Sharpe ED, Stewart JA, Hott EC. The safety and efficacy of timolol 0.5% in xanthan gum

versus timolol gel forming solution 0.5%. Curr Eye Res 2002;24:387-391.

(270) Stewart WC. Know the structure know the medicine. Review Ophthalmol 2002 Sept;34-38.

(271) Konstas AGP, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the

timolol/dorzolamide fixed combination versus latanoprost in exfoliation glaucoma. Eye 2003;17:41-46.

(272) Day DG, Schacknow PN, Wand M, Sharpe ED, Stewart JA, Leech J, Stewart WC. Timolol 0.5%/dorzolamide

2% fixed combination versus timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients

with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2003;135:138-143.


25

(273) Stewart WC, Kolker AE, Stewart JA, Leech JN, Jackson AL. Conjunctival hyperemia in healthy subjects after

short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003;135:314-320.

(274) Stewart WC, Stewart JA, Leech JN. Acute and chronic ocular symptomatology of dorzolamide 2%

compared to placebo. J Glaucoma 2003;12:151-155.

(275) Stewart WC, Stewart JA, Day DG, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed

combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand

2003;81:242-246.

(276) Stewart WC. European study assesses Xalacom. Review Ophthalmol 2003 Jun;75-77.

(277) Konstas AGP, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005% vs timolol/dorzolamide fixed combination. Ophthalmology

2003;110:1357-1360.

(278) Kałużny JJ, Szaflik J, Czechowicz-Janicka K, Kałużny J, Orzalkiewicz A, Zaleska A, Krajewska, M, Stewart JA,

Leech JN, Stewart WC. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine

2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmol Scand 2003;81:349354.

(279) Stewart WC, Stewart JA, Jenkins JN, Jackson AL. Corneal punctate staining with latanoprost, bimatoprost and travoprost. J Glaucoma 2003;12:475-479.

(280) Stewart WC, ISV-205 Study Group. Prevention of corticosteroid induced intraocular pressure elevation from

ISV-205. Arch Ophthalmol 2003;121:1543-1547.

(281) Zimmerman TJ, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching

to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 2003;19:405-415.

(282) Stewart WC, Jackson AL, Jenkins JN. Can patients guess their intraocular pressure? Am J Ophthalmol

2004;137:350-351.

(283) Konstas AGP, Hollo G, Astakhov YS, Teus MA, Akopov EL, Leech JN, Stewart WC. Factors associated with

long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol 2004;122:29-33.

(284) Sharpe ED, Day DG, Beischel CJ, Rhodes, JS, Stewart JA, Stewart WC. Brimonidine purite 0.15% vs dorzolamide 2% each given twice daily to reduce the intraocular pressure in subjects with open-angle

glaucoma or ocular hypertension. Br J Ophthalmol 2004;88:953-956.

(285) Atkinson MJ, Stewart WC, Fain JM, Stewart JA, Dhawan R, Mozaffari E, Lohs J. A new measure of patient

satisfaction with ocular hypotensive medications: The Treatment Satisfaction Survey - Intraocular Pressure

(TSS-IOP). Health Qual Life Outcomes 2003;15:1:67.

(286) Konstas AGP, Mylopoulos N, Karabatsas CH, Kozobolis VP, Diafas S, Papapanos P, Georgiadis N, Stewart

WC. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye 2004;18:893-899.

(287) Stewart WC, Day DG, Stewart JA, Holmes KT, Jenkins JN. Short-term ocular tolerability of dorzolamide 2%

and brinzolamide 1% versus placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 2004;18:905-910.

(288) Stewart WC. Review: Medical Management of Glaucoma by Tsai JC, Forbes M. Am J Ophthalmol 2004;137:218.


26

(289) Stewart WC, Geiger AC, Jenkins JN. The benefit of repeated intraocular pressure measurements in clinical

trials. Arch Ophthalmol 2004;122:936-937.

(290) Stewart WC, Jackson AL, Jenkins JN. Dropout rates for intent-to-treat and per protocol analyses. Am J

Ophthalmol 2004;137:639-645.

(291) Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol

maleate fixed combination versus concomitant brimonidine and latanoprost therapy. Eye 2004;18:990-995.

(292) Sharpe ED, Henry CJ, Mundorf TK, Day DG, Stewart JA, Jenkins JN, Stewart WC. Brimonidine 0.2% versus unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-

angle glaucoma or ocular hypertension. Eye 2005;19:35-40.

(293) Konstas AGP, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve

comparison between the fixed combinations of latanoprost/timolol and dorzolamide/timolol. Eye 2004;18:1264-1269.

(294) Stewart WC, Stewart JA, Day DG, Leech J. The safety and efficacy of unoprostone 0.15% versus

brimonidine 0.2%. Acta Ophthalmol Scand 2004;82:161-165.

(295) Hamacher T, Schinzel M, Schölzel-Klatt A, Neff H-M, Maier H, Schlaffer G, Beausencourt E, Jütte M, Scholz

R, Lorger C, Stewart WC. Short-term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from mono- and adjunctive therapies. Br J Ophthalmol

2004;88:1295-1298.

(296) Day DG, Schacknow PN, Sharpe ED, Ellyn JC, Kulze JC, Threlkeld AB, Jones ED, Brown RH, Jenkins JN,Stewart WC. A persistency and economic analysis of latanoprost, bimatoprost or beta-blockers in

patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2004;20:383-392.

(297) Konstas AGP, Bányai L, Blask K-D, Väth J, Kozobolis VP, Trüb PR, Tsironi S, Maloutas S, Teus MA, Stewart

WC. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther 2004;20:375-382.

(298) Stewart WC, Konstas AGP. Ocular and systemic side effects of latanoprost. Reply to J Kountouras et al.

Eye 2005;19:805-806.

(299) Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular pressure, safety and quality of life in

glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol 2004;14:407-415.

(300) Stewart WC. Prevention of steroid-induced intraocular pressure elevation-reply. Arch Ophthalmol

2005;123:1020.

(301) Stewart WC. Preventing steroid-induced glaucoma-reply. Arch Ophthalmol 2005;123:1018.

(302) Stewart WC, Konstas AGP, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004;20:461-469.

(303) Bayer A, Weiler W, Oeverhaus U, Skrotzki F-E, Stewart WC, Xplore Observation Group. Two-year follow-up

of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther 2004;20:470-478.

(304) Stewart WC, Jenkins JN, Johnson M. Treatment patterns for ocular hypertension. Review Ophthalmol 2004 Oct;111-117.


27

(305) Konstas AGP, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus

bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005;112:262-266.

(306) Konstas AGP, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. 24-hour intraocular pressure

short-term control with the latanoprost/timolol maleate fixed combination versus latanoprost, both dosed once each evening, in primary open-angle glaucoma patients. Arch Ophthalmol 2005;123:898-902.

(307) Konstas AGP, Karabatsas CH, Lallos N, Georgiadis N, Kotsimpou A, Stewart JA, Stewart WC. 24-hour

intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112:603-608.

(308) Day DG, Sharpe ED, Beischel CJ, Jenkins JN, Stewart JA, Stewart WC. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol 2005;15:336-

342.

(309) Stewart WC, Jenkins JN, Stewart JA. Corneal thickness after refractive surgery. Ophthalmology

2005;112:1637.

(310) Day DG, Sharpe ED, Atkinson MJ, Stewart JA, Stewart WC. The Clinical Validity of the Treatment Satisfaction Survey for Intraocular Pressure in Ocular Hypertensive and Glaucoma Patients. Eye

2006;20:583-590.

(311) Konstas AGP, Hollo G, Astakhov YS, Teus MA, Akopov EL, Jenkins JN, Stewart WC. Presentation and

longterm follow-up of exfoliation glaucoma in Greece, Spain, Russia and Hungary. Eur J Ophthalmol

2006;16:60-66.

(312) Stewart WC. Combination therapy: Is the whole greater? Review Ophthalmol 2005 Jun:60-62.

(313) Stewart WC, Jackson AL, Emkin A. Physician attitudes towards new AMD treatments. Review Ophthalmol 2005 Aug;58-60.

(314) Stewart WC, Jenkins JN, Stewart JA. Survey assesses prostaglandin use: A snap shot of how physicians are using two of the predominant glaucoma medications in their clinics. Review Ophthalmol 2005 Oct; 123-

124.

(315) Stewart WC, Heier JS, Tolentino MJ. Macugen treatment: Making it work for you. Review Ophthalmol 2005 Sept;75-77.

(316) Fiscella R, Stewart WC. Letter to the editor: Patient persistency with glaucoma therapy. J Ocul Pharmacol Ther 2005;21:349-350.

(317) Stewart WC, Passmore CL. Pharma & ophthalmology: A cautious dance. An unusual ophthalmology-

specific survey assesses how the profession views its relations with pharmaceutical companies. Review Ophthalmol 2005 Oct;51-53.

(318) Stewart WC, Day DG, Jenkins JN, Passmore CL, Stewart JA. Mean intraocular pressure and progression based on corneal thickness in primary open-angle glaucoma. J Ocul Pharmacol Ther 2006;22:26-33.

(319) Konstas AGP, Mikropoulos D, Kaltsos K, Jenkins JN, Stewart WC. 24-hour intraocular pressure control

obtained with evening versus morning dosed travoprost in primary open-angle glaucoma. Ophthalmology 2006;113:446-450.

(320) Konstas AGP, Lake S, Economou AI, Kaltsos K, Jenkins JN, Stewart WC. 24-hour control with latanoprost/timolol maleate fixed combination versus timolol maleate. Arch Ophthalmol 2006;124:1553-

1557.


28

(321) Konstas AGP, Topouzis F, Leliopoulou O, Pappas T, Georgiadis N, Jenkins JN, Stewart WC. 24-hour

intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology 2006;113:761-765.

(322) Nasser QJ, Stewart WC. Glaucoma treatment and diagnostic trends. Review Ophthalmol 2006 Mar.

(323) Konstas AGP, Kozobolis VP, Katsimpris IE, Boboridis K, Koukoula S, Jenkins JN, Stewart WC. Efficacy and

safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114:653-

657.

(324) Holló G, Chiselita D, Petkova N, Cvenkel B, Liehneova I, Izgi B, Berta A, Szaflik J, Turacli E, Stewart WC.

The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;16:816-

823.

(325) Harasymowycz P, Hutnik CML, Nicolela M, Stewart WC. The efficacy and safety of latanoprost 0.005%

versus timolol maleate 0.5% gel forming solution each given once every evening in primary open-angle

glaucoma or ocular hypertension. Can J Ophthalmol 2007;42:75-81.

(326) Greven CM, Wells JA, Stewart WC. Neovascular age-related macular degeneration and chronic VEGF

inhibition: Where do we go from here? Review Ophthalmol 2007 Feb;14.

(327) Diafas S, Day DG, Stewart JA, Stewart WC. The use of dorzolamide versus other hypotensive agents to

prevent glaucomatous progression. Ther Clin Risk Manag 2007;3:725-732.

(328) Thelen U, Christ T, Schnober D, Hofstetter H-J, Stewart WC. Mid-term response with latanoprost therapy in German ocular hypertension patients. Curr Eye Res 2007;32:51-56.

(329) Thelen U, Weiler W, Kirchhoff E, Fuchs H-B, Stewart WC. Clinical experience in the treatment of normal tension glaucoma with latanoprost in Germany. J Ocul Pharmacol Ther 2007;23:311-313.

(330) Konstas AGP, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-hour intraocular pressure lowering effect of latanoprost and dorzolamide/timolol fixed combination after 2 and 6

months of treatment. Ophthalmology 2008;115:99-103.

(331) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Cost-effectiveness of treating ocular hypertension. Ophthalmology 2008;115:94-98.

(332) Kruft B, Nelson LA, Stewart JA, Stewart WC. Adverse event reporting in ophthalmic clinical trials. Ophthalmology 2007;114:1420.

(333) Stewart WC, Feldman R, Mychaskiw MA. Ocular blood flow in glaucoma: The need for further clinical

evidence and patient outcomes research. Br J Ophthalmol 2007;91:1263-1264.

(334) Konstas AGP, Katsimpris IE, Kaltsos K, Georgiadou I, Kordelou A, Nelson LA, Stewart WC. 24-hour efficacy

of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Eye 2008;22: 1391-1397.

(335) Stewart WC, Jenkins JN. Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase

I-III to post-marketing studies. Eye 2008;22:985-988.

(336) Stewart WC, Stewart JA, Mychaskiw M. Cost-effectiveness of latanoprost and timolol maleate for the

treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye 2009;23:132-140.


29

(337) Konstas AGP, Irkec MT, Teus MA, Cvenkel B, Astakhov YS, Sharpe ED, Hollo G, Mylopoulos N, Bozkurt B,

Pizzamiglio C, Potyomkin VV, Alemu AM, Nasser QJ, Stewart JA, Stewart WC. Mean intraocular pressure and progression based on corneal thickness in patients with ocular hypertension. Eye 2009;23:73-78.

(338) Sonty S, Henry JC, Sharpe ED, Weiss MJ, Stewart JA, Nelson LA, Stewart WC. Success of switching to the dorzolamide/timolol fixed combination in patients who are insufficiently controlled by latanoprost

monotherapy and who are timolol responders. Acta Ophthalmol Scan 2008;86:419-423.

(339) Stewart WC, Konstas AGP, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115:1117-1122.

(340) Mulaney J, Sonty S, Ahmad A, Stewart JA, Stewart WC. Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. Eur J Ophthalmol 2008;18:556-562.

(341) Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res 2007;

32:1037-1043.

(342) Stewart WC, Stewart JA, Nelson LA, Kruft B. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. Eur J Ophthalmol 2008;18:199-204.

(343) Stewart WC, Stewart JA, Nelson LA, Kruft B. Mean standard deviations for common glaucoma treatments. Acta Ophthalmol Scan 2009;87:112-4.

(344) Konstas AG, Tsironi S, Vakalis AN, Nasr MB, Stewart JA, Nelson LA, Stewart WC. Intraocular pressure

control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol Scan 2009;87:71-76.

(345) Stewart WC, Feldman R, Mychaskiw MA. Reply to letter to editor regarding: Ocular blood flow in glaucoma: The need for further clinical evidence and patient outcomes research. Br J Ophthalmol 2008;92:1301-

1302.

(346) Cvenkel B, Stewart JA, Nelson LA, Stewart WC. Dorzolamide/timolol fixed combination versus

latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension.

Curr Eye Res 2008;33:163-168.

(347) Sharpe ED, Williams RD, Stewart JA, Nelson LA, Stewart WC. A comparison of dorzolamide/timolol fixed

combination versus bimatoprost in patients with open-angle glaucoma who are insufficiently controlled on latanoprost. J Ocul Pharmacol Ther 2008;24:408-413.

(348) Kałużny J, Sobecki R, Czechowicz-Janicka K, Kecik D, J. Kałużny BJ, Stewart JA, Stewart WC. Efficacy and

safety of latanoprost versus the pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scan 2008;86:860-5.

(349) Quaranta L, Pizzolante T, Riva I, Haidich AB, Konstas AGP, Stewart WC. 24-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J

Ophthalmol 2008;92:1227-1231.

(350) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Reply to Letter to the Editor, Brown GC & Brown MM, entitled, "Cost-effectiveness". Ophthalmology 2008;115:1433-1434.

(351) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Reply to Letter to the Editor, Litcher PR, entitled, "Cost-effectiveness". Ophthalmology 2008;115:1853.


30

(352) Stewart WC, Kolker AE, Sharpe ED, Day DG, Konstas AG, Hollo G, Astakhov YS, Teus MA, Stewart JA.

Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma. Eur J Ophthalmol 2008;18:765-770.

(353) Feldman RM, Stewart RH, Stewart WC, Jia G, Smugar SS, Galet VA. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma. Curr

Med Res Opin 2008;24:2403-2412.

(354) Konstas AGP, Mikropoulos D, Dimopoulos AT, Moumtzis G, Nelson LA, Stewart WC. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed

combination to latanoprost monotherapy. Br J Ophthalmol 2008;92:1498-1502.

(355) Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-

free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol 2008;2:613-621.

(356) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Glaucoma Dialogue discussing Cost-effectiveness of

treating ocular hypertension. Ophthalmology 2008;115:94-98. International Glaucoma Review 2008;

10:6-9.

(357) Alemu AM, Nelson LA, Kruft B, Stewart JA, Stewart WC. Epidemiology of glaucoma in central Ethiopia. Int

J Ophthalmol 2008;8:1729-1733.

(358) Stewart WC. Reply to Letter to the Editor, Tuulonen A & Azuara-Blanco A, entitled, "Cost-effectiveness".

Ophthalmology 2009;116:167.

(359) Stewart WC. Book review of Curbside Consultation in Glaucoma. Am J Ophthalmol 2009 Jan;147:187.

(360) Tabet R, Stewart WC, Feldman R, Konstas AGP. A Review of Additivity to Prostaglandin Analogs: Fixed and

Unfixed Combinations. Surv Ophthalmol 2008;53:S85-S92.

(361) Godfrey DA, Peplinski LS, Stewart JA, Stewart WC. A comfort comparison of travoprost BAK free 0.004%

versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2009;3:189-194.

(362) Konstas AG, Mikropoulos D. Haidich AB, Ntampos K, Stewart WC. 24-hour intraocular pressure control with

the travoprost/timolol fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol 2008;93:481-5.

(363) Sharmini AT, Yin N, Lee SS, Jackson AL, Stewart WC. Mean target intraocular pressure and progression rates in chronic angle-closure glaucoma. J Ocul Pharmacol Ther 2009;25:71-6.

(364) Seong GJ, Rho SH, Kim CS, Moon JI, Kook MS, Kim YY, Ma KT, Hong YJ, Nelson LA, Kruft B, Stewart JA,

Stewart WC. Potential benefit of intraocular pressure reduction in normal-tension glaucoma in South Korea. J Ocul Pharmacol Ther 2009;25:91-6.

(365) Konstas AGB, Pikilidou MI, Tsironi S, Mikropoulos D, Kozobolis VP, Sarafidis PA, Lasaridis AN, Nelson LA, Stewart WC. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed

combination versus timolol. Current Eye Research 2009;34:369-377.

(366) Olander KW, Galet VA, Jia G, Smugar SS, Stewart WC. Relationship between visual field severity and response to fixed combination dorzolamide/timolol or timolol alone. J Ocul Pharmacol Ther 2009;25:

357-364.

(367) Stewart WC, Kruft B, Nelson LA, Stewart JA. Ophthalmologist attitudes regarding fixed combination

treatment for glaucoma in the European Union. Eur J Ophthalmol 200919:588-593.


31

(368) Stewart WC, Konstas AGP. Reply to Letter to Editor, Mehdizadeh, Tehrani & Nowroozzadeh, entitled

"Corneal Thickness and Glaucoma Medications". Ophthalmology 2009 Jul;116;1417.

(369) Stewart WC, Konstas AGP. Reply to Letter to Editor, Rao & Sekhar, entitled, "Relative Efficacy of

Prostaglandins". Ophthalmology 2009 Jul;116;1418.

(370) Stewart WC, Stewart JA, Mychaskiw MA. Cost-effectiveness of latanoprost, travoprost and bimatoprost for

the treatment of glaucoma in Norway, Sweden and Denmark, using a decision-analytic health Economic

model. Int J Ophthalmology 2009;9:812-816.

(371) Stewart WC, Pfeiffer N, Mathis HM. Meta-analysis of articles evaluating routine intraocular pressure control

for monotherapy in the United States and Germany. Eur J Ophthalmol 2009;19;769-775.

(372) Sonty S, Mundorf TK, Stewart JA, Stewart WC. Short-Term Tolerability of Once-Daily Timolol Hemihydrate

0.5%, Timolol Maleate in Sorbate 0.5%, and Generic Timolol Maleate Gel-Forming Solution 0.5% in Glaucoma and/or Ocular Hypertension: A Prospective, Randomized, Double-Masked, Active-Controlled,

Three-Period Crossover Pilot Study. Clin Ther 2009;31:2063-2071.

(373) Stewart WC, Stewart JA, Demos CM, Turner M. Serious adverse event reporting. Ophthalmology 2009; 16:2485.

(374) Stewart WC, Kristoffersen CJ, Demos CM, Fsadni MG, Stewart JA. Incidence of conjunctiva exposure following drainage device implantation in patients with glaucoma. Eur J Ophthalmol 2010;20:124-30.

(375) Stewart WC, Stewart JA, Mychaskiw M. Response to Anderson et al. Eye 2009;23:2264.

(376) Stewart WC, Robin AL, Sharpe ED, Hennessy A, Stewart JA. The motivation to perform glaucoma clinical trials. Ophthalmology 2010;117:397.

(377) Stewart WC, Konstas AGP, Kruft B, Mathis HM, Stewart JA. Meta-analysis of 24-hour intraocular pressure fluctuation studies and the efficacy of glaucoma medicines. J Ocul Pharmacol Ther 2010;26;175-80.

(378) Alemu AM, Kristoffersen CJ, Kristoffersen MS, Stewart JA, Stewart WC. Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia. Eur J Ophthalmol 2010;

20:310-5.

(379) Pfeiffer N, Scherzer M-L, Maier H, Schoelzel S, Jasek MC, Stewart JA, Stewart WC. Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive

therapy. Clin Ophthalmol 2010;4:459-66.

(380) Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface

complaints in glaucoma patients using topical intraocular pressure-lowering medications. Cornea 2010;

29:618-21.

(381) Stewart WC, Demos CM, Turner MK, Stewart JA. Risk factors for subject withdrawals in clinical trials

evaluating glaucoma medications. Graefes Arch Clin Exp Ophthalmol 2010;248:1007-12.

(382) Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of alpha2-

adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with

prostaglandin analogs. Arch Ophthalmol 2010;128:825-33.

(383) Quaranta L, Konstas AGP, Rossetti L, Garcia-Feijoo J, O’Brien C, Nasr MB, Fogagnolo P, Demos CM, Stewart

JA, Stewart WC. Untreated 24-hour intraocular pressures measured with Goldmann applanation tonometry versus nighttime supine pressures with Perkins applanation tonometry. Eye 2010;24:1252-8.


32

(384) Holló G, Cvenkel B, Teus MA, Irkec MT, Astakhov YS, Chiselita D, Petkova N, Liehneová I, Kaluzny BJ,

Kóthy P, Bozkurt B, Akopov EL, Stewart JA, Kristoffersen MS, Kristoffersen CJ, Stewart WC. Is there any difference in target intraocular pressure for exfoliative glaucoma patients with cardiovascular disease

history? Eur J Ophthalmol 2010;20:1000-6.

(385) Lee PW, Doyle A, Stewart JA, Kristoffersen CJ, Stewart WC. Meta-analysis of timolol on the diurnal and

nighttime intraocular pressure and blood pressure. Eur J Ophthalmol 2010;20:1035-41.

(386) Stewart WC, Sharpe ED, Kristoffersen CJ, Nelson LA, Stewart JA. Association of strength of religious adherence to attitudes regarding glaucoma or ocular hypertension. Ophthalmic Res 2011;45:53-6.

(387) Stewart WC, Demos CM, Turner M, Stewart JA. Factors associated with site requirement for glaucoma clinical trials. Graefes Arch Clin Exp Ophthalmol 2010;248;1527-8.

(388) Stewart WC, Konstas AG, Quaranta L, Rossetti L, Garcia-Feijoo J, O’Brien C, Nasr MB, Fogagnolo P, Demos CM, Stewart JA. Reply to Letter to the Editor, Weinreb RN, Liu JHK, Medeiros FN, entitled "24-h intraocular

pressures measured with two tonometers". Eye 2010;24:1531-2.

(389) Konstas AG, Mikropoulos DG, Embeslidis TA, Dimopoulos AT, Papanastasiou A, Haidich A-B, Stewart WC. 24-hour intraocular pressure control with evening dosed travoprost/timolol, compared with

latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye 2010;24:1606-13.

(390) Stewart WC, Crean CS, Zink RC, Brubaker K, Haque RM, Hwang DG. Pharmacokinetics of azithromycin and

moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens.


(391) Miyashiro MJ, Lo SC, Stewart JA, Stewart WC. Efficacy, safety, and tolerability of travoprost 0.004% BAK-

free versus prior treatment with latanoprost 0.005% in Japanese patients. Clin Ophthalmol 2010;4:1355-9.

(392) Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011;36:391-398.

(393) Stewart WC, Adams MP, Stewart JA, Nelson LA. Survey of practice-related stress among United States and

European ophthalmologists. Graefes Arch Clin Exp Ophthalmol 2011;249:1277-80.

(394) Stewart WC, Magrath GN III, Demos CM, Nelson LA, Stewart JA. Predictive value of the efficacy of

glaucoma medications in animal models: Pre-clinical to regulatory studies. Br J Ophthalmol 2011;95: 1355-1360.

(395) Holló G, Thelen U, Teus MA, Quaranta L, Ferkova S, Babić N, Misiuk-Hojlo M, Mikropoulos DG, Kaluzny BJ,

Kozobolis V, Januleviciene I, Kóthy P, Camara C, Russo A, Krzyzanowska-Berkowska P, Cieślińska I, Stewart JA, Kristoffersen MS, Nelson LA, Stewart WC. Long-term outcomes of prostaglandin analog vs.

timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. J Ocul Pharmacol Ther 2011;27:493-8.

(396) Ma KT, Kim CY, Seong GJ, Lee SH, Park JW, Ha SJ, Cho BJ, Stewart JA, Kristoffersen MS, Nelson LA,

Stewart WC. Intraocular pressure reduction in normal-tension glaucoma patients in South Korea. Int Ophthalmol 2011;31:355-361.

(397) Holló G, Quaranta L, Cvenkel B, Astakhov YS, Teus MA, Kóthy P, Miglior S, Riva I, Akopov EL, Gros J, Stewart JA, Kristoffersen MS, Nelson LA, Stewart WC. Risk factors associated with progression in exfoliative

glaucoma patients. Ophthalmic Res 2011;47:208-213.


33

(398) Goldberg I, Crowston JG, Jasek MC, Stewart JA, Stewart WC. Intraocular pressure-lowering efficacy of

brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma 2012;21:55-59.

(399) Konstas AG, Quaranta L, Mikropoulos DG, Nasr MB, Russo A, Jaffee HA, Stewart JA, Stewart WC. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol

Ther 2012;28:26-32.

(400) DeMill DL, Wirostko BM, Nelson LA, Stewart JA, Stewart WC. Average eye versus highest intraocular pressure analyses in glaucoma clinical trials. Ophthalmic Res 2013;49:49-51.

(401) Sharpe RA, Nelson LA, Stewart JA, Stewart WC. Intraocular pressure efficacy of glaucoma medications versus placebo in Phase II compared to later phase trials. Br J Ophthalmol 2013;97:121-125.

(402) Stewart WC, Adams MP, Stewart JA, Nelson LA. Review of clinical medicine and religious practice. J Relig Health 2013;52:91-106.

(403) Stewart WC. Stewart JA, Kruft B, Nelson LA. Challenges facing ophthalmic startup companies in developing

new devices or medicines. Acta Ophthalmol 2013;91:e81-83.

(404) Stewart WC, Stewart JA, Nelson LA. The start-up: From dream to reality. Review Ophthalmol 2013 Apr;

62-71.

(405) Thelen U, Schnober D, Schölzel S, Kristoffersen MS, Nelson LA, Stewart JA, Stewart WC. Long-term cost

and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany. Int J Ophthalmol.

2013;6:155-159.

(406) Stewart WC, Oehler JC, Choplin NT, Markoff JI, Moster MR, Ichhpujani P, Nelson LA. A comfort survey of

timolol hemihydrate 0.5% solution once or twice daily vs. timolol maleate in sorbate. Journal of Current Glaucoma Practice, Jan-Apr 2013;7:11-16.

(407) Stewart WC, DeMill DL, Wirostko BW, Nelson LA, Stewart JA. A review of pigment dispersion and exfoliation glaucoma diagnosis on intraocular pressure in clinical trials evaluating primary open-angle

glaucoma and ocular hypertension. J Glaucoma 2013;22:506-509.

(408) Dehning DO, Nelson LA, Stewart JA, Stewart WC. Does religious adherence help diabetic patients' well-being? J Christian Nurs 2013;30:e1-11.

(409) Stewart WC, Chaney PG, Stewart JA, Kruft B, Nelson LA. Qualitative factors underlying the successful investment in new ophthalmic pharmaceutical products in the United States. Acta Ophthalmol 2013;

91:496-7.

(410) Stewart WC, Limtong AC, Magrath GN, Rembold JC, Nelson LA, Stewart JA. Lower limits of intraocular pressure in glaucoma clinical trials. J Glaucoma 2014;23:e105-7.

(411) Stewart WC, Stewart JA, Nelson LA. Doing it right: First steps in creating a pharma start-up. Review Ophthalmol 2014 Apr;54-62.

(412) Stewart WC, Stewart JA, Nelson LA. Glaucoma clinical trial design: a review of the literature. Perspect

Clin Res 2014;5:108-14.

(413) Sharpe RA, Nelson LA, Stewart JA, Stewart WC. The placebo effect in early phase glaucoma clinical trials.

Curr Eye Res 2015;40:653-6.


34

(414) Goertz AD, Stewart WC, Burns WR, Stewart JA, Nelson LA. Review of the impact of presbyopia on quality

of life in the developing and developed world. Acta Ophthalmologica 2014;92:497-500.

(415) DeMill DL, Wirostko BM, Nelson LA, Stewart WC. Upper limits of intraocular pressure in glaucoma clinical

trials. Clin Experiment Ophthalmol 2015:43:84-5.

(416) Stewart WC, Stewart JA, Nelson LA. How to assess an ophthalmic start-up. Review Ophthalmol 2015

Apr;62-9.

(417) Sharpe RA, Davidson J, Nelson LA, Stewart JA, Stewart WC. Techniques to reduce the placebo effect in glaucoma clinical trials. Ophthalmic Res 2015;54:3-5.

(418) Sharpe RA, Austin JP, Kruft B, Nelson LA, Stewart JA, Stewart WC. Description of ophthalmic pharmaceutical and device start-up companies. Ophthalmic Res 2015;54:6-9.

(419) Stewart WC, Nelson LA, Eveleth DD. Endothelial Regeneration: Help Is on the Way. Review Ophthalmol 2015 Nov;74-80.

(420) DeMill DL, Wirostko B, Stewart JA, Nelson LA, Stewart WC. Single- versus double-masking in glaucoma

clinical trials. Perspect Clin Res 2016;7:147-8.

(421) Stewart WC, Kruft B, Nelson LA, Stewart JA. Success of Ophthalmic Pharmaceutical Start-up Companies.

Acta Ophthalmol 2018;96:266-8.

(422) Stewart WC, Nelson LA, Kruft B, Stewart JA. Ophthalmic start-up CEO’s perceptions of development

hurdles. Ophthalmic Res 2018;59:110-4.

(423) Stewart WC, Nelson LA, Stewart JA. What Data Sources Do Ophthalmologists Trust? Evid Based Med. 2017;22:205-7.

(424) Stewart WC, Stewart JA, Nelson LA. Ophthalmic community perception of new medication needs. Int J Ophthalmol 2018;11:848-51.

(425) Stewart WC, Hernandez SM, Stewart JA, Nelson LA. Incidence of Ophthalmic Start-Ups. J Eye Dis Disord 2018;3:2(100119).

(426) Stewart WC, Hernandez SM, Stewart JA, Nelson LA. Orphan Drug Designations in Ophthalmology. J Eye

Dis Disord 2018;3:2(100117).

(427) Schwab D, Sturm C, Portron A, Fuerst-Recktenwald S, Hainzl D, Jordan P, Stewart WC, Tepedino ME, DuBiner H. Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to

patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study. BMJ Open

Ophthalmol 2017;1:e000063.


35

INVITED LECTURES (1) Presentation, An Overview of Glaucoma, Regional Representative Update, Duke University, Durham, NC,

November 1986.

(2) Presentation, An Overview of Visual Field Diagnosis, Ophthalmic Technician Course, Duke University, Durham, NC, March 1987.

(3) Presentation, An Overview of Glaucoma, Ophthalmic Technician Course, Duke University, Durham, NC, March 1987.

(4) Participant, Glaucoma Round-Table, South Carolina-North Carolina State Society Meeting, October 1987.

(5) Presentation, Clinical Optic Disc Diagnosis, Medical University of South Carolina Annual Meeting, Charleston, SC, May 1988.

(6) Lab Instructor, Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June

1989.

(7) Participant, Fistulizing Techniques in Laser Surgery, Special Focus Anterior Segment Laser Course,American Academy of Ophthalmology, June 1989.

(8) Participant, Anterior Segment Laser Surgery, Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June 1989.

(9) Presentation, Reopening a Fistula, Creating a Fistula, and Closing a Cyclodialysis Cleft, Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June 1989.

(10) Presentation, Pupilloplasty, Peripheral Iridoplasty, Iris Sphincterotomy, Photomydriasis, and

Goniophotocoagulation, Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June 1989.

(11) Presentation, Medical Management of Glaucoma, Regional Representative Update, Charleston SC, June 1989.

(12) Presentation, Beta Adrenergic Blockers, Regional Representative Update, Charleston SC, January 1990.

(13) Presentation, Management of the Postoperative Trabeculectomy Patient, Grand Rounds, Medical University of South Carolina, Charleston, SC, February 1990.

(14) Presentation, Glaucoma Pharmacology Update, Grand Rounds, Medical University of South Carolina,

Charleston, SC, February 1990.

(15) Presentation, Review of Cyclodestructive Procedures, Charleston Ophthalmology Society Meeting,

Charleston, SC, April 1990.

(16) Presentation, Neovascular Glaucoma, Retina Update Meeting, Medical University of South Carolina, Charleston, SC, May 1990.

(17) Presentation, Treatment of Glaucoma, Regional Representative Update, Charleston SC, August 1990.

(18) Presentation, Ocular Eye Injuries, Medical Society of Dillon, Dillon, South Carolina, August 1990.


INVITED LECTURES (continued)

36

(19) Presentation, The Secondary Glaucomas, American Academy of Ophthalmology, October 1990.

(20) Presentation, Treatment of Glaucoma, Regional Meeting, Charleston, SC, December 1990.

(21) Presentation, The Secondary Glaucomas, American Academy of Ophthalmology, October 1991.

(22) Moderator, Saturday Session, American Glaucoma Society, San Diego, CA, 1991.

(23) Presentation, Glaucoma Laser Review and Update, Grand Rounds, Medical University of South Carolina,

Charleston, SC, February 29, 1992.

(24) Presentation, Low-tension glaucoma, Grand Rounds, Medical University of South Carolina, Charleston, SC,

February 29, 1992.

(25) Presentation, Surgical Approach to Glaucoma and Cataract, Medical University of South Carolina, Department of Ophthalmology, Annual Meeting, Charleston, SC, May 22, 1992.

(26) Presentation, Clinical Evaluation and Management of Low Tension Glaucoma, American Academy of Ophthalmology, November 1992.

(27) Presentation, Current and Future Use of Glaucoma Medications, American Academy of Ophthalmology,

November 1992.

(28) Presentation, Refractory Glaucoma in Children, Medical University of South Carolina, Department of Ophthalmology, Annual Meeting, Kiawah, SC, June 13, 1993.

(29) Moderator, Wednesday Session (Mechanisms of Glaucoma and Clinical Observations), American and European Glaucoma Societies Meeting, Iceland, July 7, 1993.

(30) Presentation, Clinical Evaluation and Management of Low Tension Glaucoma, American Academy of Ophthalmology, November 1993.


November 1993.

(32) Presentation, Medical Treatment of Glaucoma, Kansas City Society of Ophthalmology and Otolaryngology,

Annual Clinical Conference, December 9-10, 1993.

(33) Presentation, Visual Field Interpretation, Kansas City Society of Ophthalmology and Otolaryngology, Annual

Clinical Conference, December 9-10, 1993.

(34) Presentation, Dealing with Glaucoma Suspects, Kansas City Society of Ophthalmology and Otolaryngology,

Annual Clinical Conference, December 9-10, 1993.

(35) Moderator, Carteolol Advisory Board Meeting, Rancho Mirage, CA, February 26, 1994.

(36) Presentation, Current and Future Use of Glaucoma Medications, Scandinavian Symposium, Stockholm,

Sweden, April 24, 1994.

(37) Presentation, Diagnosis and Management of Early Glaucoma, 27th Panhellenic Ophthalmological Congress,

May 27, 1994.

(38) Presentation, Medical Therapy of Glaucoma, 27th Panhellenic Ophthalmological Congress, May 27, 1994.



37

(39) Participation, Round-table Treatment Problems in Glaucoma, 27th Panhellenic Ophthalmological Congress, May 27, 1994.

(40) Participation, Round-table Diagnostic Problems in Glaucoma, 27th Panhellenic Ophthalmological Congress, May 28, 1994.

(41) Presentation, Future of Glaucoma Research, Basel, Switzerland, May 31, 1994.

(42) Presentation, Low-Tension Glaucoma, Richland County Ophthalmology Society, July 26, 1994.

(43) Discussant, Johnstone MA: Incidence of Endophthalmitis After Mitomycin Filtering Surgery in 508 Eyes,

American Academy of Ophthalmology, November 2, 1994.

(44) Presentation, Serum Lipid Levels and the Ophthalmologist, Parker Health Lecture, American Academy of Ophthalmology, October 31, 1994.

(45) Moderator, Changing Perspectives in the Clinician's Viewpoint, OAPI advisory board meeting, Florida Keys,

January 14, 1995.

(46) Presentation, New and Current Glaucoma Medications, Cincinnati, Ohio, March 29, 1995.

(47) Presentation, Medical Treatment of Glaucoma, Louisville, Kentucky, June 13, 1995.

(48) Presentation, Prostaglandin Update, Prostaglandin Symposium, Society of Ophthalmologists of Europe,

Milan, Italy, June 27, 1995.

(49) Presentation, Prostaglandin Update, Prostaglandin Symposium, Society of Ophthalmologists of Europe,

Milan, Italy, June 28, 1995.

(50) Presentation, Glaucoma Update, Grand Rounds, Kansas City, Missouri, August 24, 1995.

(51) Chairman, Neuroprotection Session, International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics, Geneva, Switzerland, September 30, 1995.

(52) Presentation, Future of Glaucoma Therapy, Zürich, Switzerland, October 2, 1995.

(53) Presentation, Overview of Diagnosis and Treatment of Glaucoma, Training Session, Charleston, SC,

October 10, 1995.

(54) Participant, Future of Glaucoma Therapy, Round-Table, Rockville, MD, October 14, 1995.

(55) Presentation, Clinical Evaluation and Management of Low-Tension Glaucoma, American Academy of Ophthalmology, Atlanta, GA, October 30, 1995.

(56) Presentation, Apraclonidine, Glaucoma Diagnostic and Therapeutic Progress Scientific Session (in

combination with Prevent Blindness America meeting), American Academy of Ophthalmology, Atlanta, GA,

November 1, 1995.


Atlanta, GA, November 2, 1995.

(58) Presentation, Review and Management of Glaucoma, South Carolina Satellite Symposium, December 12,

1995.

(59) Presentation, Betimol Research Potential, Research & Development and Marketing, Atlanta, GA, January

1996.



38

(60) Presentation, Results of Blood Pressure in Carteolol vs. Timolol Maleate Study, OAPI advisory meeting,

Palm Springs, CA, February 17, 1996.

(61) Chairman and Panel Discussion Leader, Betimol, Advisory Board Session, Miami, FL, February 1996.

(62) Presentation, New and Future Medicines, Atlanta, GA, April 1996.

(63) Presentation, Xalatan Update, PIOP annual meeting, Dallas, TX, April 29, 1996.

(64) Presentation, Betimol Overview, California Drug Regulatory Agency, June, 1996.

(65) Presentation, New and Future Medicines, National Ophthalmics Speakers Program, Ottawa, Canada, June

21, 1996.

(66) Presentation, New Therapies in Glaucoma, Capetown, South Africa, July 4-7, 1996.

(67) Moderator, Surgery Session, Capetown, South Africa, July 4-7, 1996.

(68) Participant, Panel Discussion, Capetown, South Africa, July 4-7, 1996.

(69) Presentation, Treatment of Glaucoma, Training Seminar, Kalamazoo, Michigan, July 11, 1996.

(70) Presentation, Xalatan Overview, Training Seminar, Kalamazoo, Michigan, July 11, 1996.

(71) Presentation, Xalatan Update, Central South Carolina Society Meeting, Columbia, SC, July 23, 1996.

(72) Presentation, New Medical Therapies in Glaucoma, University of South Carolina Grand Rounds, Columbia,

SC, July 12, 1996.

(73) Presentation, New Medical Therapies in Glaucoma, New Orleans, LA, July 26, 1996.

(74) Presentation, Current Medicines in Glaucoma, Xalatan launch meeting, Dallas, Texas, August 21, 1996.

(75) Presentation, Xalatan Overview, Xalatan launch meeting, Dallas, Texas, August 21, 1996.

(76) Presentation, New Medicines in Glaucoma, 29th Panhellenic Ophthalmological Congress, Greece,

September 1996.

(77) Presentation, Clinical Evaluation and Management of Low-Tension Glaucoma, American Academy of Ophthalmology, Chicago, October 1996.


Chicago, October 1996.

(79) Presentation, Results of Cost Analysis of Glaucoma Chronic Dosing Therapy, Betimol Advisory Board,

Chicago, October 28, 1996.

(80) Presentation, Diurnal Curve of Intraocular Pressure with Rescula Treatment, Chicago, October 29, 1996.

(81) Presentation, Current and Future Glaucoma Medications, East Virginia Medical School, Norfolk, VA,

November 13, 1996.

(82) Presentation, Grand rounds, East Virginia Medical School, Norfolk, VA, November 13, 1996.

(83) Presentation, Current and Future Glaucoma Medications, Daytona Beach, FL, January 15, 1997.

(84) Presentation, Xalatan and Alphagan Overview, Puerto Rico, February 12, 1997.



39

(85) Participant, Panel Discussion, Puerto Rico, February 12, 1997.

(86) Presentation, Treatment of Glaucoma, Training Seminar, Kalamazoo, Michigan, February 20, 1997.

(87) Presentation, Xalatan Overview, Training Seminar, Kalamazoo, Michigan, February 20, 1997.

(88) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Buenos Aires, Argentina, April 7,

1997.

(89) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Buenos Aires, Argentina, April 8,

1997.

(90) Presentation, Current and future glaucoma medications, Scandanavian Ophthalmology Meeting, Iceland,

April 18 - 20, 1997.

(91) Participant, Panel Discussion, Scandinavian Ophthalmology Meeting, Iceland, April 18 - 20, 1997.

(92) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Cancun, Mexico, May 3, 1997.

(93) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Pan American Ophthalmology Conference, Cancun, Mexico, May 3, 1997.

(94) Presentation Rescula: A New Agent for the Treatment of Glaucoma, International Congress of Glaucoma,

Sao Paulo, Brazil, May 8, 1997.

(95) Participant, Panel Discussion, Betimol and Modern ß-blocker Therapy, Ophthalmology Times, Fort

Lauderdale, Florida, May 1997.

(96) Presentation, Patient Management Considerations in Glaucoma, EuroTransMed, London, May 20, 1997.

(97) Presentation, Xalatan Overview, National Ophthalmics Speakers Program, Quebec, Canada, June13, 1997.

(98) Presentation, Xalatan Overview, Charleston Ophthalmology Society, Charleston, South Carolina, July 8,

1997.

(99) Presentation, Today’s ß-blocker therapies: The place of Betimol™ in the Commercial Market, Atlanta,

Georgia, July 28, 1997.

(100) Presentation, New and Future Drug use for Glaucoma, American Academy of Ophthalmology, San

Francisco, California, October 27, 1997.

(101) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, San Francisco, California, October 29,

1997.

(102) Presentation, Current and Future Glaucoma Medications, Ottawa, Canada, November 5, 1997.

(103) Presentation, Postoperative Complications of Filtering Surgery, Training session, Ottawa, Canada,

November 5, 1997.

(104) Presentation, Xalatan Overview, Charlotte, North Carolina, November 17, 1997.

(105) Presentation, Current and Future Glaucoma Medications, 48th Annual Post-Graduate Review Course: Ophthalmology, Syracuse, New York, December 5, 1997.

(106) Presentation, Xalatan Overview, 48th Annual Post-Graduate Review Course: Ophthalmology, Syracuse,

New York, December 5, 1997.



40

(107) Presentation, Treating Primary Open-Angle Glaucoma, 75th Southern Congress of Optometry, Atlanta,

Georgia, February 26, 1998.

(108) Presentation, Current and Future Glaucoma Medications, San Antonio Ophthalmology Society, San Antonio,

Texas, February 28, 1998.

(109) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Jerusalem, Israel, March 18, 1998.

(110) Chairman, IOP Lowering Therapies, 2nd International Glaucoma Symposium, Jerusalem, Israel, March 18,

1998.

(111) Presentation, Treating Primary Open-Angle Glaucoma, Helsinki, Finland, March 27, 1998.

(112) Presentation, Treating Primary Open-Angle Glaucoma,, Tampere, Finland, March 27, 1998.

(113) Presentation, Treating Primary Open-Angle Glaucoma,, Stockholm, Sweden, March 28, 1998.

(114) Moderator, Round-table discussion, Current ß-blocker Therapy, ARVO, Fort Lauderdale Florida, May 10,

1998.

(115) Presentation, Treating Primary Open-Angle Glaucoma,, Halkadiki, Greece, May 27, 1998

(116) Participant, Panel Discussion Combined Surgery, Halkadiki, Greece, May 28, 1998

(117) Presentation, Development and Pharmacology of Latanoprost, Banff, Canada, June 25, 1998

(118) Presentation, The Role of IOP in the Management of Glaucoma, Banff, Canada, June 25, 1998

(119) Presentation, Update on Compliance, New York City, New York, July 17, 1998

(120) Presentation, Development and Pharmacology of Latanoprost & Clinical Efficacy and Safety of Latanoprost,

New Orleans, Louisianna, September 17, 1998

(121) Presentation, Development and Pharmacology of Latanoprost & Clinical Efficacy and Safety of Latanoprost, San Antonio, Texas, September 18, 1998

(122) Presentation, Treating Primary Open-Angle Glaucoma, Glaucoma Symposium, Richmond, Virginia, September 25, 1998

(123) Presentation, New and Future Drug use for Glaucoma, Risquez Hospital Post Graduate Course, Caracas,

Venezuela, October 2-4, 1998

(124) Participant, Panel Discussion Treating Glaucoma, Risquez Hospital Post Graduate Course, Caracas,


(125) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Risquez Hospital Post Graduate Course, Caracas, Venezuela, October 2-4, 1998

(126) Presentation, Update on Compliance, Risquez Hospital Post Graduate Course, Caracas, Venezuela, October 2-4, 1998

(127) Presentation, Treating Primary Open-Angle Glaucoma, Risquez Hospital Post Graduate Course, Caracas,




41

(128) Presentation, Treating Primary Open-Angle Glaucoma, Macon, Georgia, October 15, 1998

(129) Presentation, Aggressive Lowering of IOP, American Academy of Ophthalmology, New Orleans, Louisiana, November 7, 1998

(130) Presentation, The Role of IOP in the Management of Glaucoma, American Academy of Ophthalmology, New Orleans, Louisiana, November 8, 1998

(131) Presentation, New and Future Drug use for Glaucoma, American Academy of Ophthalmology, New Orleans, Louisiana, November 11, 1998

(132) Presentation, Pharmacology of Glaucoma Medications, Inter-American Course, Bascom Palmer Eye Institute, Miami, FL, November 18, 1998

(133) Presentation, New Medical Therapy in Glaucoma: Making Clinical Decisions with Drugs, Inter-American Course, Bascom Palmer Eye Institute, Miami, FL, November 18, 1998

(134) Presentation, The Role of IOP in the Management of Glaucoma, Banff, Canada, November 21, 1998

(135) Presentation, The Role of IOP in the Management of Glaucoma, Winnipeg, Canada, December 5, 1998

(136) Presentation, The Role of IOP in the Management of Glaucoma, Niagara-on-the-Lake, Ontario, March 27,

1999

(137) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, San Antonio Ophthalmological Society,

University of Texas, San Antonio, TX, April 17, 1999

(138) Presentation, The Role of IOP in the Management of Glaucoma, Ottawa, Canada, April 24, 1999

(139) Moderator, Rescula Advisory Board, Fort Lauderdale, FL, May 8, 1999

(140) Presentation, Clinical Efficacy of Rescula, Fort Lauderdale, FL, May 8, 1999

(141) Presentation, Position of Rescula in Glaucoma Therapy, Fort Lauderdale, FL, May 8, 1999

(142) Presentation, Key Factors for Treatment Success in Glaucoma, White Nights Ophthalmological Congress,

St. Petersburg, Russia, May 24 - 27, 1999

(143) Presentation, Treating Primary Open-Angle Glaucoma, Memphis Eye Society Annual Convention, University

of Tennessee, Memphis, TN, June 5, 1999

(144) Presentation, New and Future Drug use for Glaucoma, Memphis Eye Society Annual Convention, University of Tennessee, Memphis, TN, June 5, 1999

(145) Presentation, Update on Compliance, Memphis Eye Society Annual Convention, University of Tennessee,

Memphis, TN, June 5, 1999

(146) Presentation, Current Treatment of Glaucoma, Pharmacist Society of NY, Albany, NY, June 24, 1999

(147) Presentation, Key Factors for Treatment Success in Glaucoma, X11th Congress of the European Society of Ophthalmology, Stockholm, Sweden, June 27 - July 1, 1999

(148) Presentation, Treating Primary Open-Angle Glaucoma, X11th Congress of the European Society of Ophthalmology, Stockholm, Sweden, June 27 - July 1, 1999



42

(149) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Buenos Aires, Argentina, August 20, 1999

(150) Presentation, Current Treatment and Endpoints in Glaucoma, Buenos Aires, Argentina, August 20, 1999

(151) Presentation, Current Treatment and Endpoints in Glaucoma, McGill University, Montreal, Canada,

September 9, 1999

(152) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Montreal,

September 9, 1999

(153) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Quebec City, September 10, 1999

(154) Presentation, Development and Pharmacology of Latanoprost, Charleston, SC, September 25, 1999

(155) Presentation, Switching Medicines in Glaucoma, AAO, Orlando, FL, October 23, 1999

(156) Presentation, Role of IOP in Management of Glaucoma, AAO, Orlando, FL, October 24, 1999

(157) Presentation, New and Future Medical Treatment for Glaucoma, AAO, Orlando, FL, October 26, 1999

(158) Presentation, Treating Primary Open-Angle Glaucoma, JCAHPO, Orlando, FL, October 27, 1999

(159) Presentation, Lessons from the Neurosciences, ISOPP Congress, Lisbon, Portugal, February 10, 2000

(160) Chairman, Glaucoma Session, ISOPP Congress, Lisbon, Portugal, February 10, 2000

(161) Participant, Panel Discussion, Blood Flow, ISOPP Congress, Lisbon, Portugal, February 10, 2000

(162) Presentation, Stepwise Treatment of Glaucoma, ISOPP Congress, Lisbon, Portugal, February 10, 2000

(163) Presentation, Clinical Results of Rescula, Islamorada, FL, March, 2000

(164) Presentation, Efficacy and Safety of Cosopt, National Glaucoma Congress, Athens, Greece, March 31, 2000

(165) Presentation, Mechanism of Xalatan, Glaucoma Update 2000, Miami, FL, April 7, 2000

(166) Presentation, Efficacy & Safety of Cosopt, Spring Ophthalmic Consultants’ Conference, Charleston, SC, April

15, 2000

(167) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Budapest,

Hungary, April 25, 2000

(168) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Tallinn, Estonia,

April 26, 2000

(169) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, 2nd Polish Glaucoma Symposium, Wroclaw, Poland, April 28, 2000

(170) Presentation, Current Monotherapy in Glaucoma, London, Ontario, May 12, 2000

(171) Presentation, Current Monotherapy in Glaucoma, Toronto, Ontario, May 13, 2000



43

(172) Chairman, Rescula United States Advisory Board, St. Thomas, Virgin Islands, June 2-4, 2000

(173) Presentation, Rescula Efficacy Update, St. Thomas, Virgin Islands, June 2-4, 2000

(174) Presentation, Rescula Safety Update, St. Thomas, Virgin Islands, June 3, 2000

(175) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Niagara on the

Lake, Ontario, June 10, 2000

(176) Presentation, Over view of Xalatan, Niagara on the Lake, Ontario, June 10, 2000

(177) Presentation, Mechanism of Action of Xalatan, Las Vegas, Nevada, June 21, 2000

(178) Presentation, Development and Pharmacology of Xalatan, New York, New York, August 12, 2000

(179) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Tampere,

Finland, September 1, 2000

(180) Presentation, Clinical Trials of Unoprostone, New York, New York, September 16, 2000

(181) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, St. Louis

Ophthalmological Society, Grand Rounds, St. Louis University, St. Louis, Missouri, September 21, 2000

(182) Presentation, New and Future Medical Treatment for Glaucoma, Grand Rounds, St. Louis University, St.

Louis, Missouri, September 22, 2000

(183) Presentation, Pharmacology and Clinical Effects of Xalatan, International Society of Ocular Toxicology,

Kiawah Island, South Carolina, October 4, 2000

(184) Presentation, Development and Pharmacology of Xalatan, Washington DC, October 14, 2000

(185) Presentation, New and Future Medical Treatment for Glaucoma, AAO, Dallas, Texas, October 24, 2000

(186) Presentation, Emerging Therapies in the Medical Management of Glaucoma, AAO, Dallas, Texas, October 22, 2000

(187) Presentation, Development and Pharmacology of Xalatan, Dorado, Puerto Rico, November 4, 2000

(188) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Ottawa, Ontario, November 14, 2000

(189) Presentation, Clinical Results of Rescula, Biloxi, Mississippi, November 18, 2000

(190) Presentation, Overview of Glaucoma, Specialized Glaucoma Representative Training, Peapack, New Jersey, February 13, 2001

(191) Presentation, Overview of Ophthalmic Equipment, Specialized Glaucoma Representative Training, Peapack,

New Jersey, February 13, 2001

(192) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Grand Rounds, University of Cincinnati, Cincinnati, Ohio, February 14, 2001



44

(193) Presentation, Emerging Medical Treatment for Glaucoma, Cincinnati Society of Ophthalmology, Cincinnati, Ohio, February 14, 2001

(194) Presentation, Adjunctive Therapy, Atlanta, Georgia, February 21, 2001

(195) Presentation, Place of Rescula in Therapy, Atlanta, Georgia, February 21, 2001

(196) Presentation, The Efficacy and Safety of Unoprostone in the Management of Glaucoma, SECO International 2001, Atlanta, Georgia, February 23, 2001

(197) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Halifax, Nova

Scotia, March 3, 2001

(198) Presentation, Efficacy and Safety of Cosopt, 8th International Congress on Glaucoma, Athens, Greece,

March 10, 2001

(199) Presentation, Overview of Xalatan, AXIS, Anaheim, California, March 14, 2001

(200) Presentation, New and Future Medical Treatment for Glaucoma, New York, New York, April 19, 2001

(201) Chairman, Round-Table Discussion, Rescula Advisory Board, Fort Lauderdale, Florida, April 29, 2001

(202) Presentation, Development and Pharmacology of Latanoprost, Montreal, Canada, May 4-6, 2001

(203) Presentation, Pressure Control or Neuroprotection: Where are we in Glaucoma Therapy? Niagara-on-the-Lake, Canada, June 9, 2001

(204) Presentation, Development and Pharmacology of Latanoprost, Keystone, Colorado, June 22-24, 2001

(205) Chairman, Cascade Meeting, Keystone, Colorado, June 22-24, 2001

(206) Presentation, Development and Pharmacology of Latanoprost, Toronto, Canada, August 17-19, 2001

(207) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Columbus, Ohio, September 20, 2001

(208) Presentation, New Prostaglandin Related Medicines, Midwestern Glaucoma Society, Sponsored by Washington University, St. Louis, Missouri, October 6, 2001

(209) Presentation, Xalacom: The Dynamic Duo, European Xalacom Launch, Cannes, France, October 16, 2001

(210) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Indianapolis, Indiana, November 1, 2001

(211) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Louisville, Kentucky, November 7, 2001

(212) Presentation, Research Methodology: Reading Between the Lines, Laval University, Quebec City, Canada,

November 8, 2001

(213) Presentation, Neuroprotection and Blood Flow: Putting it in Perspective, Quebec City, Canada, November 8,

2001



45

(214) Presentation, Xalacom versus Combination Timolol and Alphagan, American Academy of Ophthalmology, New Orleans, Louisiana, November 12, 2001

(215) Presentation, Medical Options for Primary Open-angle Glaucoma, Nashville, Tennessee, November 28, 2001

(216) Speaker and Key Faculty, Xalatan Safety Update, East Coast Summit Meeting, Miami, Florida, December 1, 2001

(217) Presentation, Importance of IOP, European Xalacom Launch, Cannes, France, January 16, 2002

(218) Presentation, Study Design & Literature Analysis, Glaucoma Science Liaison Training, Banff, Alberta, Canada, January 19, 2002

(219) Presentation, Clinical Review of Xalacom, Xalacom Launch, Caracas, Venezuela, February 21, 2002

(220) Chairman, Round-Table Discussion, Xalacom Launch, Caracas, Venezuela, February 22, 2002

(221) Presentation, Glaucoma Genetics, Clinical Applications: ISV-205, International Symposium on Ocular Pharmacology and Pharmaceutics, Seville, Spain, February 28, 2002

(222) Moderator, Glaucoma Genetic Therapy Session, International Symposium on Ocular Pharmacology and Pharmaceutics, Seville, Spain, February 28, 2002

(223) Presentation, Overview of Xalatan, International Symposium on Ocular Pharmacology and Pharmaceutics,

Seville, Spain, February 28, 2002

(224) Moderator, Latanoprost Update – The New “Gold Standard” for Medical Treatment of Intraocular Pressure, International Symposium on Ocular Pharmacology and Pharmaceutics, Seville, Spain, February 28, 2002

(225) Presentation, Mechanism of Action between Prostaglandins, Glaucoma Update (Cascade) Meeting, Puerto Rico, April 6, 2002

(226) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Evansville, Indiana, April 9, 2002

(227) Presentation, Clinical Review of Xalacom, Greek Glaucoma Symposium, Athens, Greece, April 13, 2002

(228) Presentation, Medical Options for Monotherapy, Southfield, Michigan, April 25, 2002

(229) Presentation, Reading Between the Lines: An Interpretation of Clinical Studies, Magog, Quebec, Canada,

April 27, 2002

(230) Presentation, Xalacom versus Cosopt, Xalacom Launch, Paris, France, May 13, 2002

(231) Presentation, Mechanism of Action between Prostaglandins, Glaucoma Update (Cascade) Meeting,

Montreal, Quebec, Canada, May 18, 2002

(232) Moderator, Managed Care Consultant Panel, Glaucoma Update (Cascade) Meeting, Montreal, Quebec,

Canada, May 18, 2002

(233) Presentation, Ocular Hyperemia and the Significance of the OHTS Trial, Chicago, Illinois, May 21, 2002



46

(234) Presentation, Review of the New Prostaglandin Related Medicines in Comparison to Latanoprost, 35th

Panhellenic Ophthamological Congress, Sponsored by the Ophthalmology Society of Northern Greece and Pharmacia, Chalkidiki, Greece, June 5, 2002

(235) Presentation, New Prostaglandin Related Medicines, Sponsored by the University of Missouri, Kansas City,

Missouri, June 15, 2002

(236) Press Conference, Clinical Review of Xalacom, Bangkok, Hong Kong, June 27, 2002

(237) Presentation, Clinical Review of Xalacom, Shantou, China, June 28, 2002

(238) Presentation and Key Faculty, Neuroprotection and Blood Flow: Putting it into Perspective, Glaucoma Update 2002 Cascade Meeting, Boston, Massachusetts, July 13, 2002

(239) Presentation, Importance of IOP and Diurnal Curve, Santiago, Chile, July 26, 2002

(240) Presentation, Clinical Review of Xalacom, Santiago, Chile, July 26, 2002

(241) Presentation, Glaucoma Medication Compliance Review, Santiago, Chile, July 26, 2002

(242) Presentation, Clinical Review of Xalacom, Ophthalmological Society of Malaysian Medical Association Meeting, Kuala Lumpur, Malaysia, August 2, 2002

(243) Presentation, Importance of IOP, Ophthalmological Society of Malaysian Medical Association Meeting, Kuala Lumpur, Malaysia, August 2, 2002

(244) Presentation, Overview of Latanoprost, 5th Singapore National Eye Centre International Meeting and 5th Worldeyes International Meeting, Singapore, August 3, 2002

(245) Presentation, Importance of IOP, 5th Singapore National Eye Centre International Meeting and 5th Worldeyes International Meeting, Singapore, August 3, 2002

(246) Presentation, Clinical Review of Xalacom, Bangkok, Thailand, August 4, 2002

(247) Presentation, Importance of IOP, Bangkok, Thailand, August 4, 2002

(248) Presentation, Overview of Glaucoma, Toronto, Canada, August 23, 2002

(249) Presentation, Medical Options for Monotherapy, Toronto, Canada, August 23, 2002

(250) Presentation, Clinical Review of Xalacom, Porto, Portugal, September 14, 2002

(251) Presentation, Clinical Review of Xalacom, Lisbon, Portugal, September 15, 2002

(252) Presentation, Clinical Review of Xalacom, National Sales Meeting, Toronto, Canada, September 24, 2002

(253) Presentation, Ocular Hypertension and the Importance of IOP, SEAGIG Convention, Manila, Philippines,

September 27, 2002

(254) Presentation, AXIS Update, AAO, Orlando, Florida, October 21, 2002

(255) Presentation, Prostaglandin Therapy - What We Know Today, Marina del Ray, CA, November 2, 2002



47

(256) Moderator, Glaucoma Managed Care Advisory Board Meeting, Marina del Ray, CA, November 2, 2002

(257) Presentation, Clinical Review of Xalacom, Vancouver, Canada, February 8, 2003

(258) Presentation, Importance of IOP, Vancouver, Canada, February 8, 2003

(259) Presentation, Importance of IOP, 10th International Congress of Glaucoma, Athens, Greece, February 22,

2003

(260) Presentation, Clinical Review of Cosopt, 10th International Congress of Glaucoma, Athens, Greece, February

22, 2003

(261) Presentation, Controlling IOP with Cosopt, Clinical Frontiers in Ophthalmology, Krakow, Poland, March 8, 2003

(262) Moderator, Speaker Forum, Cosopt IOP Lowering Efficacy, Clinical Frontiers in Ophthalmology, Krakow, Poland, March 9, 2003

(263) Presentation, Achieving Powerful IOP Control in Clinical Practice, 4th International Glaucoma Symposium,

Barcelona, Spain, March 20, 2003

(264) Co-Chair, Medical Therapy 2, 4th International Glaucoma Symposium, Barcelona, Spain, March 22, 2003

(265) Presentation, 24-hour Diurnal Curve Comparison of Bimatoprost versus Timolol Maleate/Dorzolamide Fixed Combination, 4th International Glaucoma Symposium, Barcelona, Spain, March 22, 2003

(266) Presentation, Controlling IOP with Cosopt, National Glaucoma Congress, Utrecht, Netherlands, May 23,

2003

(267) Presentation, Ocular Blood Flow, Glaucoma in the 21st Century, Istanbul, Turkey, May 24, 2003

(268) Presentation, Overview of Xalacom, Glaucoma in the 21st Century, Istanbul, Turkey, May 24, 2003

(269) Presentation, Overview of Xalacom, Eye 2 Eye Rounds, Niagara-on-the-Lake, May 31, 2003

(270) Presentation, Major Clinical Studies Comparing Latanoprost, Bimatoprost and Travoprost, Mont Tremblant, Quebec, June 10, 2003

(271) Presentation, Current Clinical Status Between Latanoprost, Bimatoprost and Travoprost, Mont Tremblant,

Quebec, June 10, 2003

(272) Presentation, Overview of Xalacom, Mont Tremblant, Quebec, June 10, 2003

(273) Presentation, Rationale of Glaucoma Prostaglandin F2 Drugs, Boston, MA, June 29, 2003

(274) Trainer, Workshop – Blood Flow Update, Vascular Risk Factors, Blood Flow Update, Vascular Risk Factors – Slide Kit Review, Cancun, Mexico, July 11, 2003

(275) Presentation, Controlling IOP with Cosopt, Blood Flow Update, Vascular Risk Factors – Slide Kit Review,

Cancun, Mexico, July 12, 2003

(276) Presentation, Pharmaceutical Research Network, LLC, New York City, NY, July 16, 2003



48

(277) Presentation, Achieving Powerful IOP Control in Clinical Practice, SEO, 79th Congreso de la Sociedad Espanola de Oftalmologia, Valencia, Spain, October, 10, 2003.

(278) Presentation, Future of Glaucoma Therapy, Savannah, Georgia, October 15, 2003.

(279) Presentation, Importance of IOP, EUCAN Product Planning Meeting, London, England, October 22, 2003.

(280) Presentation, Clinical Overview of Comparators, London, England, October 22, 2003.

(281) Presentation, Future of Glaucoma Therapy, Central South Carolina Ophthalmological Society, Columbia,

South Carolina, October 28, 2003.

(282) Presentation, Importance of IOP, Barcelona, Spain, November 22, 2003.

(283) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Cologne,

Germany, December 6, 2003.

(284) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Bremen, Germany,

January 17, 2004.

(285) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Baden-Baden, Germany, January 24, 2004.

(286) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Munich, Germany, February 14, 2004.

(287) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Berlin, Germany,

March 6, 2004.

(288) Moderator, Prostaglandins in the Eye, International Symposium on Ocular Pharmacology and Therapeutics,

Monte Carlo, Monaco, March 12, 2004.

(289) Presentation, Persistency of Glaucoma Therapy, International Symposium on Ocular Pharmacology and Therapeutics, Monte Carlo, Monaco, March 12, 2004.

(290) Presentation, Newer Developments in Glaucoma Treatment, 11th International Congress of Glaucoma,

Athens, Greece, March 13, 2004.

(291) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Heidelberg, Germany, March 27, 2004.

(292) Presentation, Overview of Rescula, The Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, April 25, 2004.

(293) Presentation, Prostaglandin Review, American Society of Cataract and Refractive Surgery, San Diego,

California, May 2, 2004.

(294) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Dusseldorf,

Germany, May 15, 2004.

(295) Presentation, Efficacy and Safety of Cosopt, Barcelona, Spain, May 21, 2004.

(296) Presentation, Overview of Xalacom, Winnipeg, Manitoba, Canada, May 25, 2004.



49

(297) Presentation, Blood Flow, 37th Panhellenic and International Congress, Halkidiki, Greece, June 11, 2004.

(298) Presentation, Overview of Fixed Combinations, 37th Panhellenic and International Congress, Halkidiki,

Greece, June 12, 2004.

(299) Presentation, The Role of Prostaglandin Analogues in the Treatment of Glaucoma: Learnings from Recent

Guidelines, Kuala Lumpur, Malaysia, June 21, 2004.

(300) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, Hospital Universiti Sainz Malaysia,

Kota Bahru, Malaysia, June 22, 2004.

(301) Presentation, The Role of Prostaglandin Analogues in the Treatment of Glaucoma: Learnings from Recent Guidelines, Penang, Malaysia, June 23, 2004.

(302) Presentation, Emerging New Standard of Glaucoma Management, Hong Kong Eye Hospital, Kowoon, Hong Kong, June 24, 2004.

(303) Presentation, Emerging New Standard of Glaucoma Management, Kowoon, Hong Kong, June 24, 2004.

(304) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, Taichung, Taiwan, June 25, 2004.

(305) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, Taipei, Taiwan, June 26, 2004.

(306) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, Kaohsiung, Taiwan, June 27, 2004.

(307) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Klink, Germany,

July 3, 2004.

(308) Presentation, Importance of IOP, Warsaw, Poland, September 12, 2004.

(309) Presentation, Importance of IOP/Review of Latanoprost, Progress in Glaucoma Therapy, Wolfsburg, Germany, October 2, 2004.

(310) Presentation, Importance of IOP/Review of Cosopt, University of Liverpool, Warrington Hospital, Cheshire,United Kingdom, November 15, 2004.

(311) Presentation, Importance of IOP/Review of Cosopt, Manchester Royal Eye Society, Manchester, United

Kingdom, November 15, 2004.

(312) Presentation, Importance of IOP/Review of Cosopt, University of Newcastle, Newcastle, United Kingdom,

November 16, 2004.

(313) Presentation, Importance of IOP/Review of Cosopt, James Cook University, Chester, United Kingdom,

November 16, 2004.

(314) Presentation, Importance of IOP/Review of Cosopt, Swansea, Wales, United Kingdom, November 17, 2004.

(315) Presentation, Importance of IOP/Review of Cosopt, North Trent Ophthalmological Society, Sheffield, United

Kingdom, November 18, 2004.

(316) Presentation, Importance of IOP/Review of Cosopt, Norfolk/Norwich University, Norwich, United Kingdom,

November 19, 2004.



50

(317) Presentation, 24-hr IOP Control with Travoprost, 12th Greek Glaucoma Congress, Athens, Greece, March 5, 2005.

(318) Presentation, Future of Glaucoma Therapy, 12th Greek Glaucoma Congress, Athens, Greece, March 5, 2005.

(319) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Sydney, Australia, March 14, 2005.

(320) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Brisbane, Australia,

March 15, 2005.

(321) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Perth, Australia,

March 16, 2005.

(322) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Adelaide, Australia,

March 17, 2005.

(323) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Melbourne, Australia, March 18, 2005.

(324) Presentation, Update on the Latanoprost/Timolol Fixed Combination, 20th Asia Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, March 28, 2005.

(325) Press brief, Update on the Latanoprost/Timolol Fixed Combination, 20th Asia Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, March 28, 2005.

(326) Presentation, Update on Latanoprost, VIII International Congress of the Pan Arab African Council of Ophthalmology, Dubai, United Arab Emirates, April 8, 2005.

(327) Presentation, Overview of Medical Glaucoma Treatments, Riyadh, Saudi Arabia, June 5, 2005.

(328) Presentation, Overview of Medical Glaucoma Treatments, Damman, Saudi Arabia, June 6, 2005.

(329) Presentation, Overview of Medical Glaucoma Treatments, Jeddah, Saudi Arabia, June 7, 2005.

(330) Presentation, Update on Latanoprost, AfME Ophthalmology Symposium, Cairo, Egypt, June 9, 2005.

(331) Presentation, Overview of Diurnal Fluctuation, Turkish Ophthalmic Society Meeting, Ankara, Turkey, September 20, 2005.

(332) Presentation, Prostaglandin analogues: clinical efficacy and adjunctive therapy management, Turkish Ophthalmic Society Meeting, Ankara, Turkey, September 20, 2005.

(333) Presentation, Update on the Latanoprost/Timolol Fixed Combination, Korean Ophthalmology Autumn Congress, Seoul, Korea, October 8, 2005.

(334) Presentation, Importance of IOP and Review of Cosopt, Asian Angle-Closure Glaucoma Club Annual Congress, Taipei, Taiwan, October 29, 2005.

(335) Presentation, Importance of IOP, Asian Angle-Closure Glaucoma Club Annual Congress, Taipei, Taiwan,

October 30, 2005.



51

(336) Presentation, Travoprost adjunctive therapy study (TATS), TATS Investigators Meeting and Speakers Training, Athens, Greece, February 11, 2006.

(337) Interview, Betimol, Vistakon Pharmaceuticals, 2006 National Sales Meeting, Palm Springs, Florida, February 28, 2006.

(338) Session moderator, Target pressures in glaucoma therapy, Alcon National Masters Club, Las Vegas, Nevada, March 13, 2006.

(339) Presentation, Overview of Fixed Combination Therapy, Alcon National Masters Club, Las Vegas,

Nevada,March 13, 2006.

(340) Presentation, Overview of diurnal fluctuations, V Russian Ophthalmic School, Moscow, Russia, March 17,

2006.

(341) Presentation, Prostaglandin analogues: clinical efficacy and adjunctive therapy management, Dusseldorf,

Germany, March 24, 2006.

(342) Presentation, Ocular Blood Flow and Glaucoma, CEE-Istanbul University Program, Istanbul, Turkey, March 25, 2006.

(343) Session moderator, Does ocular blood flow really matter despite of strong IOP reduction, CEE-Istanbul University Program, Istanbul, Turkey, March 25, 2006.

(344) Presentation, 24-hour IOP Control and the Benefits of PM Dosing, 3rd AfME Ophthalmology Forum,

Dubai,United Arab Emirates, April 13, 2006.

(345) Presentation, An Overview of Monotherapy and Fixed Combination Therapy, 3rd AfME Ophthalmology Forum, Dubai, United Arab Emirates, April 13, 2006.

(346) Session chair, Xalacom Speaker Training, 3rd AfME Ophthalmology Forum, Dubai, United Arab Emirates,

April 13, 2006.

(347) Presentation, Overview of Fixed Combination Therapy, 5th Glaucoma Symposium, Wroclaw, Poland, April

21, 2006.

(348) Presentation, Overview of prostaglandin therapy, 13th Annual Scientific Meeting of the Canadian Society of Cataract and Refractive Surgery, Montreal, Quebec, Canada, April 23, 2006.

(349) Presentation, Clinical review of the latanoprost/timolol fixed combination, 39th Panhellenic Ophthalmological Congress, Thessaloniki, Greece, June 9, 2006.

(350) Presentation, PG analogs as a first line treatment of glaucoma in the US, Lodz, Poland, June 12, 2006.

(351) Presentation, The role of prostaglandin based fixed combinations in the treatment of glaucoma, Lodz, Poland, June 12, 2006.

(352) Presentation, Overview of Diurnal Fluctuation, Siena, Italy, June 16, 2006.

(353) Presentation, Overview of Fixed Combination Therapy, Sydney, Australia, July 23, 2006.

(354) Presentation, CM 05-10 ADAPT: Brinzolamide compared to placebo when added to travoprost/timolol fixed combination, Investigator meeting, Sydney, Australia, July 23, 2006.



52

(355) Presentation, Overview of Fixed Combination Therapy, Cape Town, South Africa, August 22, 2006.

(356) Presentation, Overview of Fixed Combination Therapy, Port Elizabeth, South Africa, August 22, 2006.

(357) Presentation, Overview of Fixed Combination Therapy, Johannesburg, South Africa, August 22, 2006.

(358) Presentation, Overview of Fixed Combination Therapy, Durban, South Africa, August 22, 2006.

(359) Presentation, Overview of Fixed Combination Therapy, Investigator meeting, Montreal, Canada, November 18, 2006.

(360) Presentation, CM 05-10 ADAPT: Brinzolamide compared to placebo when added to travoprost/timolol fixed

combination, Investigator meeting, Montreal, Canada, November 18, 2006.

(361) Presentation, Overview of Fixed Combination Therapy, Investigator meeting, Frankfurt, Germany,

December 16, 2006.

(362) Presentation, CM 06-12: Success of switching to the travoprost/timolol fixed combination from prior mono-

or adjunctive therapy in Germany, Investigator meeting, Frankfurt, Germany, December 16, 2006.

(363) Presentation, Overview of Prostaglandin Therapy, Glaucoma Update Meeting, Oxfordshire, England, March 10, 2007.

(364) Presentation, Travoprost-based IOP control in primary and adjunctive treatment, Izmir, Turkey, March 19, 2007.

(365) Presentation, Travoprost-based IOP control in primary and adjunctive treatment, Adana, Turkey, March 19,

2007.

(366) Presentation, Pseudoexfolitive Glaucoma, Lindberg Society, International Glaucoma Symposium, Athens,

Greece, March 31, 2007.

(367) Presentation, Overview of glaucoma and research methods, Zurich, Switzerland, August 24, 2007.

(368) Presentation, Overview of Prostaglandin Therapy, Orford, Quebec, Canada, September 15, 2007.

(369) Moderator, Poster session 3: Neuro-ophthalmology / Strabismology / Paediatric / History, Glaucoma,

Physiology/Biochemistry/Pharmacology, European Association for Vision and Eye Research, Portoroz,

Slovenia, October 6, 2007.

(370) Moderator, AMD advisory board, American Academy of Ophthalmology, November 10, 2007.

(371) Moderator, Glaucoma advisory board, American Academy of Ophthalmology, November 11, 2007.

(372) Presentation, Inspire Protocol 041-103, Investigator meeting, Raleigh, NC, December 8, 2007.

(373) Presentation, Loteprenol Etabonate: A New Generation Steriod Against Ocular Inflammation, 41st Panhellenic Ophthalmological Congress, Thessaloniki, Greece, May 29, 2008.

(374) Presentation, Prostaglandin Update: 2008, 41st Panhellenic Ophthalmological Congress, Thessaloniki,

Greece, May 30, 2008.



53

(375) Presentation, Second line therapy with Cosopt or Xalacom versus adding Cosopt to Xalatan monotherapy, 41st Panhellenic Ophthalmological Congress, Thessaloniki, Greece, May 30, 2008.

(376) Moderator, Rescula Advisory Board, American Academy of Ophthalmology, San Francisco, CA, October 25, 2009.

(377) Presentation, Rescula safety, tolerability and efficacy, American Academy of Ophthalmology, San Francisco, CA, October 25, 2009.

(378) Presentation, Where do we get all those new medicines anyway? The challenge of today’s new drug

development, West Haven, CT, July 17, 2011.

(379) Presentation, The Placebo Effect in Glaucoma Trials: Impact, Potential Causes And Solutions, Acucela

Investigator Meeting, Chicago, IL, August 13, 2011.

(380) Presentation, The Placebo Effect in Glaucoma Trials: Impact, Potential Causes And Solutions, Altheos

Investigator Meeting, San Francisco, CA, December 3, 2011.

(381) Presentation, ARVO Workshop: Starting a company, Ophthalmic start-up CEO’s perceptions of development hurdles, The Association for Vision and Research in Ophthalmology, Seattle, Washington,

May 2, 2016.


54

MISCELLANEOUS (1) Stewart WC: Glaucoma: When to treat and what to use. Audio Digest Ophthalmology, Volume 32,

Number 04, February 17, 1994, ISSN 0271-1281.

FELLOWS

Research Fellows: Clinical Fellows:

Mark A. Cascairo, D.O. Hugh L. Hennis, M.D. Tod A. McMillan, M.D. Matthew J. Nutaitis, M.D.

David R. Gwynn, M.D.

Gesa A. Stroman, M.D. Sirus Hamzavi, M.D.

Xiao-hong Wang, M.D. Tarek Ragaiey, Ph.D.

Chris Lopresto, M.D.

Wen-Jing Jiang, M.D. Savvas Diafas, M.D.

Qasiem Nasser, M.D.


55

ACADEMIA (1) Editorial board, Journal of Glaucoma, 1991 - 1994.

(2) Review board member for Journal of Glaucoma, 1991 –

(3) Review board member for American Journal of Ophthalmology, 1991 –

(4) Review board member for Archives of Ophthalmology, 1992 –

(5) Review board member for Archives of Dermatology, 1991 – 1996

(6) Review board member for Investigative Ophthalmology and Visual Science, 1994

(7) Review board member for Survey of Ophthalmology, 1994 –

(8) Review board member for SLACK, Inc., 1990.

(9) Review board member for Ophthalmology, 1995 –

(10) Review board member for Ophthalmic Surgery, 1996 –

(11) Review board member for British Journal of Ophthalmology, 1999 –

(12) Review board member for Medical Letter, 1997 –

(13) Review board member for Comprehensive Ophthalmology, 2000 –

(14) Review board member for Eye, 2000 –

(15) Review board member for Ocular Surgery & Lasers, 2002 –

(16) Review board member for Acta Ophthalmologica Scandinavica, 2002.

(17) Review board member for Drugs & Aging. 2004 –

(18) Review board member for European Journal of Ophthalmology. 2004 –

(19) Instructor for Merck, Sharp and Dohme Corporation, 1989 -

(20) Program Committee, American Glaucoma Society, 1990-1993.

(21) Glaucoma Advisory Committee, Prevent Blindness America, 1990 - 1996.

(22) Ethics committee, South Carolina Society of Ophthalmology, 1991.

(23) Organizing board and Chairman of the Glaucoma section of International Symposium on

Experimental & Ocular Pharmacology and Pharmaceutics, 1995 –2004.

(24) Editorial board, Ophthalmologia (Greece), 2004.

(25) Editorial board, Acta Ophthalmologica Scandinavica, 2007 –


56

(26) Editorial board, Journal of Ocular Pharmacology and Therapeutics, 2008.

MEETINGS DEVELOPED

(1) Diagnostic and therapeutic update in glaucoma, Kiawah, SC, April, 1991.

(2) Investigator meeting, Tampere, Finland, August, 2002.

(3) Investigator meeting, Toronto, Ontario, Canada, August 2002.

(4) Investigator meeting, Barcelona, Spain, November 2003.

(5) Investigator meeting, Warsaw, Poland, August, 2004.

(6) Investigator meeting, Wroclaw, Poland, April, 2006.

(7) Investigator meeting, Sydney, Australia, July 2006.

(8) Investigator meeting, Montreal, Canada, November 2006.

(9) Investigator meeting, Frankfurt, Germany, December 2006.

Documents

CURRICULUM VITAE WILLIAM C. STEWART, MD PRN … · WILLIAM C. STEWART, MD 4 PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES (1) Advisory Board member, Pharmos Pharmaceuticals, 1989